

CURRICULUM VITAE

Updated date: 2/21/2020

A. PERSONAL INFORMATION

American Name: Nelson Chen, Ph.D.
Official Name: Zhengjia Chen, Ph.D.
Business Address: Associate Professor,
Division of Epidemiology and Biostatistics
School of Public Health
1603 West Taylor Street, SPHPI 947
&
Director,
Biostatistics Shared Core Resource Core
University of Illinois Cancer Center
University of Illinois at Chicago
818 South Wolcott Avenue, Room 524
Chicago, IL 60612
Business Phone: 312-413-7059(SPH), 312-996-6027(Cancer Center)
E-mail: znchen@uic.edu

B. EDUCATION

Ph.D. in Biostatistics, University of Southern California, Los Angeles, CA, 2008
Ph.D Dissertation: PHASE I CLINICAL TRIAL DESIGNS (Range and Trend of Expected Toxicity Level in Standard A+B Designs and an Extended Isotonic Design Treating Toxicity as a Quasi-Continuous Variable).

M.S. in Biometry, University of Southern California, Los Angeles, CA, 2001
Master Thesis: Ethnic Differences in Mammographic Density.

M.S. in Biochemistry and Molecular Biology, Peking University, Beijing, P.R.China, 1998
Masters Thesis: Genetic Engineering of Metallothionein in Cyanobacteria.

B.S. in Microbiology, Peking University, Beijing, P.R.China, 1995.
Bachelor Thesis: Characterization of Metallothionein from Cyanobacteria.

C. AWARDS OR HONORS.

2017: International Chinese Statistical Association (ICSA) Significant Contribution Award as Treasurer at the 2016 ICSA Applied Statistics Symposium.

2016: Award for Outstanding Service to Clinical and Translational Research Committee (CTRC) at Winship Cancer Institute

2013: Award for Dedication to High Quality Oncology Research and Commitment to Clinical and Translational Research Committee (CTRC) at Winship Cancer Institute

08/1999- 07/2001: University of Southern California
Honor: Research Scholarships.

08/1998- 07/1999: University of Southern California
Honor: Fellowship.

09/1995-07/1998: Peking University, Beijing, P.R.China
Honors: Excellent M.S. thesis.

09/1990-07/1995: Peking University, Beijing, P.R.China
Honors: Exemption of Entrance Examination to Graduate School

D. PROFESSIONAL EXPERIENCES

2/16/2020-Present
Associate Professor,
Division of Epidemiology and Biostatistics
School of Public Health
University of Illinois at Chicago

2/16/2020-Present
Director
Biostatistics Shared Resources Core
University of Illinois Cancer Center

1/1/2015-2/15/2020
Research Associate Professor,
Department of Biostatistics and Bioinformatics
Department of Hematology and Medical Oncology
Department of Radiology and Imaging Sciences
Emory University

8/1/2009-12/31/2014
Research Assistant Professor,
Department of Biostatistics and Bioinformatics
Department of Hematology and Medical Oncology
Department of Radiology and Imaging Sciences
Emory University

08/2010-2/15/2020:

Co-Director of Biostatistics and Bioinformatics Core of Lung Cancer SPORE, Winship Cancer Institute, Emory University.

01/2019-2/15/2020:

Leading Biostatistician of Clinical and Translational Research Committee (CTRC) at Winship Cancer Institute, Emory University

01/2011-2/15/2020:

Leading Biostatistician of Phase I Unit of Winship Cancer Institute, Emory University

06/2018 -2/15/2020:

Director of Biostatistics and Informatics Core of GI SPORE, Winship Cancer Institute, Emory University

01/2019-2/15/2020:

Director of Biostatistics and Informatics Core of Head & Neck SPORE, Winship Cancer Institute, Emory University

08/2011-12/2018:

Co-Director of Biostatistics and Informatics Core of Head & Neck SPORE, Winship Cancer Institute, Emory University

08/2010- present:

Co-Director of Biostatistics and Bioinformatics Core of Lung Cancer PO1, Winship Cancer Institute, Emory University

5/2003 – 7/2009:

Statistician at Children's Oncology Group, CureSearch, Arcadia, California

1/2001 – 4/2003

Programmer/Analyst at University of Southern California, Los Angeles, California

9/1994 – 7/1998

Research Assistant at Peking University, Beijing, P.R.China

E. COMMITTEE MEMBERSHIPS

- Executive Committee of International Chinese Statistical Association (ICSA) 2016 Applied Statistics Symposium in Atlanta.
- Curriculum Committee in Department of Biostatistics & Bioinformatics, Emory University. 2010 to present.
- Collaborative Committee in Department of Biostatistics & Bioinformatics, Emory University. 2013 to present.
- Clinical and Translational Research Committee (CTRC) at Winship Cancer Institute, Emory University. 2010 to present.

- Full member of the Discovery & Developmental Therapeutics (DDT) program at Winship Cancer Institute, Emory University. 2009 to present.

F. PROFESSIONAL APPOINTMENTS and ACTIVITIES

National Grant Review

2019 – June: Member, Clinical Oncology (CONC) Study Section, Center for Scientific Review, Bethesda, MD.

February 2018 – present: Statistician of National Institute of Allergy and Infectious Diseases (NIAID) Host Directed Therapy for Tuberculosis and HIV Co-Infection.

January 2018: Grant Reviewer of Nevada IDEa Network of Biomedical Research Excellence (INBRE) program of NIH.

Local Grant Review

2016 Member of review committee of Research Technologies Program at the Atlanta Clinical & Translational Science Institute (ACTSI).

2014 Member of Emory University Research Committee (URC), Atlanta, Georgia.

Professional Activities

Organizer and Chair of an invited session entitled “Novel Statistical Methods for Big Health Data” at ICSA 2019 International Conference in Hangzhou, China.

Organizer and Chair of an invited session entitled “Utilization of Big Data in Precision Medicine” at ICSA 2019 International Conference in Hangzhou, China.

Organizer and Chair of an invited session entitled “Adaptive Methods and Regulation for Clinical Trials” at 2016 ICSA Applied Statistics Symposium in Atlanta.

Chair of an invited session entitled “Semiparametric statistical methods for complex data” at 2016 ICSA Applied Statistics Symposium in Atlanta.

G. TEACHING EXPERIENCE

Lecturer at Emory University and Winship Cancer Institute.

Course Number	Course Title	Credit Hours	Number of students enrolled
2019 Summer Semester	BIOS 500S: Phase I Clinical Trials in Emory SIBS 2019	NA	NA
2019 Spring Semester	Bois 520 Clinical Trial Methodology (Sole Instructor)	2	37

2018 Summer Semester	BIOS 500S: Phase I Clinical Trials in Emory SIBS 2018	NA	NA
2018 Spring Semester	Statistics in oncology overview	NA	About 15
2017 Summer Semester	BIOS 500S: Phase I Clinical Trials in Emory SIBS 2017	NA	NA
2017 Spring Semester	Bois 520 Clinical Trial Methodology (Sole Instructor)	2	36
2016 Fall Semester	Journal Club of Medical Fellows (Statistical lecturer on Phase I clinical trial design)	NA	About 25
2015 Spring Semester	Bois 520 Clinical Trial Methodology (Sole Instructor)	2	30
	Journal Club of Medical Fellows (Statistical lecturer on Phase I clinical trial design)	NA	About 25
2014 Spring Semester	Journal Club of Medical Fellows (Statistical lecturer on Phase I clinical trial design)	NA	About 20
2013 Spring Semester	Bois 520 Clinical Trial Methodology (Sole Instructor)	2	21
	Bois 520M Clinical Trial (A lecture on interim analysis)	2	About 20
	Journal Club of Medical Fellows (Statistical lecturer on Phase I clinical trial design)	NA	About 30
2012 Fall Semester	Fundamentals of Clinical Research (Statistical lecturer on clinical trial)	2	About 6
2011 Spring Semester	Bois 520 Clinical Trial Methodology (Sole Instructor)	2	22
	Journal Club of Medical Fellows (Statistical lecturer)	NA	About 20
2010 Fall Semester	Fundamentals of Clinical Research (Statistical lecturer on clinical trial)	2	About 7
	Journal Club of Medical Fellows (Statistical lecturer)	NA	About 20
2010 Spring Semester	Journal Club of Medical Fellows (Statistical lecturer)	NA	About 20
	Winship Elkin Lecture (A lecture on Phase I clinical trial design)	NA	About 40

Teaching Assistant at Division of Biostatistics, Department of Preventive Medicine, University of Southern California.

- 2009 Spring semester: PM511. Data Analysis.
- 2008 Fall semester: PM522. Introduction to the Theory of Statistics

– 2008 Spring semester: PM510. Principle of Biostatistics

G. Students Mentoring

* PhD Dissertation Advisor

1. Yuzi Zhang, PhD, Dept. of Biostatistics and Bioinformatics, Emory University, 2018-Present. “Advanced Bayesian Approaches for Early Phase Clinical Trials”.
2. Ye Cui, PhD, (jointly advising with Dr. Runyan Luo, PhD), Dept. of Mathematics and Statistics, Georgia State University, 2010-2013 (Graduated). “Advanced Designs of Cancer Phase I and Phase II Clinical Trials”.

MPH Thesis Advisor

1. Yi Lasanajak, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2012-2013. (graduated). “Evaluation of Significant Biomarkers Associated with Progression Free Survival and Overall Survival in Thyroid Cancer Patients”.
2. Zheng Li, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2012-2014. (graduated). “Dose Escalation with Over-dose and Under-dose Controls for Phase I/II Clinical Trials”. **Won the Shepard Award for the best thesis of the Department of Biostatistics and Bioinformatics 2014.**
3. Run Zhang, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2014-2016. (graduated). “Escalation with overdose control using normalized equivalent toxicity score and patient’s characteristics to define personalized maximum tolerated dose in phase I clinical trial”. **Won the Shepard Award for the best thesis of the Department of Biostatistics and Bioinformatics 2016.**
4. Zheyu Hu, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2014-2016. (graduated). “Racial disparities in multiple myeloma”.
5. Yufan Chen, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2016-2017. (graduated). “Survival Analysis of Patients with Acute Myeloid Leukemia”.
6. Yuzi Zhang, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2016-2018. (graduated). “Adaptive Bayesian Phase I Clinical Trial Designs for Estimating the Maximum Tolerated Doses for Two Drugs while Fully Utilizing all Toxicity Information”.
7. Chaejin Kim, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2016-2018. (graduated). “Partitioning Around Medoids Clustering in Follicular Lymphoma Patients: Comparison with FLIPI and FLIPI2 in PFS”.
8. Tianyu Gao, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2017-2018. (graduated). “ Safety of Administering Pegfilgrastim on the Same Day of Continuously infused 5-Fluorouracil (5-FU) for Patients With Gastrointestinal (GI) Malignancies: A Retrospective Study”.
9. Tianyi Xu, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2017-2018. (graduated). “Impacts and Improvement in Delineation of the lumpectomy Cavity Boost Volume by using 3-D Implantable Tissue Markers”.

10. Youyun Zheng, BS, Dept. of Computer Science, Emory University, 2016-2018. (**graduated with the highest honor**). “Interactive Software for Dose Recommendation and Simulation of Phase I Cancer Clinical Trial Using EWOC-NETS Design”.
11. Bokai Zhao, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2018-2019. (graduated). “Investigation of Multiple Biomarkers in Predicting the Disease Free Survival and Overall Survival Among Head and Neck Cancer Patients”.
12. Chenyue Yang, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2018-2019. (graduated). “Effect Of 5-FU Bolus on Survival in Patients with Metastatic Colorectal Cancer Treated with Combination Chemotherapy”.
13. Jiapeng Shuang, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2018-2019. (graduated). “Real-world Outcomes of Immune Checkpoint Inhibitors (ICI) in Lung Cancer Patients”.
14. Tao Liang, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2018-2019. (graduated). “Impact of uncommon genomic alterations on outcomes in metastatic colorectal cancer patients”.
15. Yawen Wang, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2018-2019. (graduated). “Association between breast cosmesis and two common radiotherapy regimens”.
16. Zeyuan Wang, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2018-2019. (graduated). “Effect of Lipid-Lowering Therapy on Epicardial Adipose Tissue Radiodensity in Hyperlipidemic Post-Menopausal Women”.

MPH Student Thesis Reader

1. Shaoman Yin, MS, Department of Biostatistics, Emory University, 2012-2013. (graduated). “Analyzing Durability and Efficacy of Long-lasting Insecticide-treated Bed Nets: A Longitudinal Monitoring Study at Western Kenya”.

Internship Provided

1. Zhibo Wang, MS, Dept. of Mathematics and Statistics, Georgia State University, 2010-2012. “Development of Statistical Software for Phase I Clinical Trials”.
2. Jing Sun, MS, Dept. of Computer Science, Emory University, 2010. “Development of Statistical Software for Phase I Clinical Trials”.
3. Anran Liu, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2014. “Escalation with overdose control using normalized equivalent toxicity score and patient’s characteristics to define personalized maximum tolerated dose in phase I clinical trial”.

Research Assistantship Provided

1. Zheng Li, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2012-2014. “Advanced Designs of Cancer Phase I Clinical Trials”.

Supervisor of Students for Practicum

1. Xiaojing Wang, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2012-2013.

2. Songli Xu, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2009-2010.
3. Chang Liu, MS, Dept. of Biostatistics and Bioinformatics, Emory University, 2012-2013.
4. Xiaowei Liu, MS, Dept. of Actual Science, Georgia State University, 2013-2014.
5. Anqi Pan, BS, Dept. of Biostatistics and Bioinformatics, Emory University, 2015-2016.
“Prevalence of Zinc Deficiency in Patients with Upper GI Cancer on Chemotherapy”.
6. Ishaan Amit Dave, BS, Dept. of Biostatistics and Bioinformatics, Emory University, 2016.
“EWOC-NETS for combination of two drugs in cancer Phase I clinical trial”.
7. Yuzi Zhang, BS, Dept. of Biostatistics and Bioinformatics, Emory University, 2016-Present.
8. Chaejin Kim, BS, Dept. of Biostatistics and Bioinformatics, Emory University, 2016-Present.
9. Wanqi Chen, BS, Dept. of Biostatistics and Bioinformatics, Emory University, 2018-Present.
10. Weixing Huang, BS, Dept. of Biostatistics and Bioinformatics, Emory University, 2018-Present.

H. EDITOR AND REVIEWER OF THE JOURNALS

Editors:

1. Guest Editor of Journal of Probability and Statistics
2. Editor of New Journal of Science
3. Associate Editor of Clinical Cancer Research Letter
4. Member of Editorial Board of Journal of Bioinformatics, Computational and Systems Biology

Reviewer:

Statistical Journals:

1. Biometrics.
2. Biostatistics.
3. Statistics in Medicine.
4. Statistics in Biopharmaceutical Research.
5. Contemporary Clinical Trial.
6. Pharmaceutical Statistics
7. Journal of Biopharmaceutical Statistics
8. Journal of Bioinformatics, Computational and Systems Biology

Other Scientific Journals:

1. Journal of Clinical Oncology.
2. Cancer.
3. Pediatric Blood and Cancer.
4. Ethnicity and Disease.
5. Neuro-Oncology.
6. International Journal of Epidemiology.
7. Plos One.

I. MEMBERSHIP OF PROFESSIONAL ASSOCIATIONS

1. 2002 to present, Member of American Statistical Association (ASA)
2. 2009 to present, Member of International Chinese Statistics Association (ICSA).
3. 2003 to present, Member of Children Oncology Group (COG).
4. 2008 to present, Member of The Society for Clinical Trials (SCT).
5. 2002 to present, Member of American Association of Cancer Research (AACR).

J. GRANTS

ACTIVE GRANTS

4 P30 CA138292-08S1 (W. Curran) 04/07/09-03/31/22

NIH/NCI \$1,400,000

Emory Winship Cancer Institute Cancer Center Support Grant

This Cancer Center Support Grant provides NCI support for the Administration, Research Programs, Shared Resources, Clinical trials and developmental funds for the Winship Cancer Institute of Emory University.

Role: Co-Director of Biostatistics and Biomedical Informatics Core

Effort: 20%

1 P50 CA217691-01A1 (Ramalingam) 06/01/19-08/31/24

NIH/NCI \$1,474,358 (Bios Core 3)

Emory University Lung Cancer SPORE

This SPORE grant is to improve response to immunotherapy in NSCLC and develop novel targeted agents for resistant NSCLC.

Role: Co-Director of Biostatistics and Biomedical Informatics Core (Bios Core 3)

Effort: 20%

HHSN261201800037C (Chen, G.) 07/01/18- 06/30/19

OCEAN NANOTECH \$427,529

Quantum Dot FRET Immunoassay to Quantify Intramolecular Epitopes of Analytes in Tissue Sections

The objective of this project is to develop a quantum dot (QD)-based immunoassay to quantify activated growth signal transducers using proximity technology of Fluorescence Resonance Energy Transfer (FRET). We hypothesize that a ratio of activated signal transducers usually as phosphorylated proteins to their total protein levels in cancer cells can be determined by FRET signal. Quantification of activated growth signal transducer is critical for us to understand cancer cell progression and evaluate anti-cancer therapies which aim to block growth signaling pathway and induce apoptosis.

Role: Co-Investigator

Effort: 3%

5 R01 CA140515-09 (Chen, J.) 08/01/15-07/31/20

NIH/NCI \$252,098

Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling

In this proposal, we plan to explore the molecular mechanisms by which oncogenic BRAF V600E “rewires” metabolic and cell signaling networks and signals through transcription factor Oct-1 to promote the HMGCL-acetoacetate axis that selectively enhances BRAF V600E-dependent tumor development.

Role: Co-Investigator

Effort: 5%

1 R01 CA201340-01 (Marcus) 12/16/15-08/30/20
NIH/NCI \$228,750

Defining Early Escape Strategies in LKB1 Mutant Lung Cancer

The goal of this project is to define how LKB1 loss impacts lung cancer metastasis.

Therefore, we hypothesize that LKB1-mutant cells use EMT to initially invade through the basement membrane, which is followed by defective FAK-based adhesion signaling that allows cells to navigate the collagen microenvironment during metastasis.

Role: Co-Investigator

Effort: 5%

1 R01 CA194027-01A1 (Marcus) 12/04/15-11/30/20
NIH/NCI \$323,257

Developing a Pharmacologic Approach to Treat LKB1 Mutant NSCLC

The objectives of this proposal are i) to determine if pharmacologic FAK inhibition can specifically suppress the metastasis of Lkb1-mutant lung tumors in vivo and ii) define which clinically observed LKB1 mutations cause pFAK 397 activation and create a tumor vulnerability targetable by pharmacologic FAK inhibition.

Role: Co-Investigator

Effort: 4%

PC160820P1 (Liu) 09/01/17-08/31/20
US DOD \$157,346

Multimodality Imaging Platform for Neurovascular Bundle Sparing Prostate Radiotherapy to Preserve Sexual Function

The ultimate goal is to develop MRI-guided “Neurovascular Bundle Sparing (NVB) prostate radiotherapy, advance imaging technology to assess treatment-related erectile dysfunction and thereby improve sexual outcomes and quality of life in prostate-cancer survivors.

Role: Co-Investigator

Effort: 5%

1R01 CA207768-01A1 (Kang) 7/1/2017 - 6/30/2022
NIH/NCI \$250,000

Role of MAST1 kinase in cisplatin resistant cancers

Our central hypothesis is that MAST1 provides cisplatin-resistant proliferative signals through its potential substrate and effectors in cancer cells. Thus, MAST1 signaling represents a promising anti-cancer target in combination with cisplatin.

Role: Co-Investigator

Effort: 5%

- 5 R01 CA203388 -02 (Mao) 04/01/17-03/31/21
NIH/NCI \$275,949
2DR MR Correlational Spectroscopy Platform for Molecular and Genetic Characterizations of Glioma
This research is to develop a clinically implemented a 2D COSY platform for non-invasive genetically classifying and characterizing gliomas in patients using an onco- metabolite R(-)-2-hydroxyglutarate, (2-HG) as a biomarker of heterozygous mutations in the isocitrate dehydrogenase (IDH1 and IDH2) genes.
Role: Co-Investigator
Effort: 5%
- 1R01CA223220-01A1 (Sun) 07/01/18-06/30/23
NIH \$275,133
Modulation of death receptor 4in EGFR-targeted cancer therapy
This proposal is to understand the mechanism and biological significance of death receptor 4downregulation during EGFR-targeted cancer therapy.
Role: Co-Investigator
Effort: 5%
- 1R01CA228414 (Lesinski) 04/01/18-03/31/22
NIH \$333,238
Targeted MEK inhibition to enhance immunotherapy in cholangiocarcinoma
This proposal is to investigate whether MEKi will synergize with PD-L1 blockade to elicit anti-tumor immune responses via altering cytokine and chemokine signatures that promote CD8⁺ T cell infiltration and survival and decreased immunosuppressive cells in the TME.
Role: Co-Investigator
Effort: 5%
- 7 R01CA208253-03 (Lesinski) 09/15/17-07/31/22
NIH/NCI \$228,511
Enhancing immune therapy in pancreatic cancer by targeting IL-6
This proposal will enhance our understanding of how the stroma influences carcinogenesis and immune suppression in PDAC.
Role: Co-Investigator
Effort: 5%
- W81XWH-17-1-0186 (Kang) 09/01/17-08/31/19
US/DoD \$200,000
Signaling and targeting of glutamate dehydrogenase 1 in metastatic non-small cell lung carcinoma
The goal of the proposed research is to decipher the mechanism of metabolic enzyme GDH1-dependent regulation of metastasis and to validate GDH1 as a novel therapeutic target in the treatment of metastatic lung carcinoma using GDH1 small molecule inhibitor R162.
Role: Co-Investigator
Effort: 5%

1R01CA215718-01A1 (Yang) 02/01/18-01/31/23
NIH/NCI \$356,850

Multiparametric MRI-guided Prostate HDR Brachytherapy with Focal Tumor Boost.
The proposed personalized mp-MRI-guided HDR brachytherapy based on accurate prostate segmentation and registration technologies has two clinical benefits: (1) to improve long-term survival and (2) to reduce the side effects.

Role: Co-Investigator
Effort: 5%

1R01HL143350-02 (Garcia) 07/01/18-06/30/22
NIH/NHLBI \$442,618

Quantification of myocardial blood flow using Dynamic PEC/CAT fused imagery to determine physiological significance of specific coronary lesions
The aim of this work is to develop software tools to fuse coronary anatomy data obtained from CT coronary angiography with dynamic PET data (combination of anatomic and physiologic information) to noninvasively measure absolute myocardial blood flow, flow reserve and relative flow reserve across specific coronary lesions.

Role: Co-Investigator
Effort: 5%

1 R01 CA175316-01A1 (Kang) 04/01/19-02/28/24
NIH/NCI \$207,500

Transcription-dependent and -independent Signaling of RSK2 in Cancer Metastasis
In this proposal, we will examine the role of RSK2 as a signal integrator in metastatic cells by phosphorylating and regulating multiple protein factors to provide anti-apoptosis, pro-invasive and pro-metastatic signals in cancer cells, and validate RSK2 signaling pathways in combination with others as an alternative therapeutic target in treatment of metastatic cancers using a novel RSK inhibitor FMK-MEA.

Role: Co-Investigator
Effort: 5%

5 R01 CA203388 -02 (Mao) 04/01/17-03/31/21
NIH/NCI \$275,949

2DR MR Correlational Spectroscopy Platform for Molecular and Genetic Characterizations of Glioma.

This research is to develop a clinically implemented a 2D COSY platform for non-invasive genetically classifying and characterizing gliomas in patients using an onco-metabolite R(-)-2-hydroxyglutarate, (2-HG) as a biomarker of heterozygous mutations in the isocitrate dehydrogenase (IDH1 and IDH2) genes.

Role: Co-Investigator
Effort: 5%

PC180599 (Olson) 08/01/2019 – 07/31/2022
US DOD \$600,000

Targeting Rb loss using BET inhibition to reprogram the prostate tumor microenvironment and enhance the efficacy of immunotherapy.

We seek to determine if Rb loss decreases T cell infiltration into the tumor microenvironment and can be reprogrammed using BET inhibition. We hypothesize that Rb-deficient cancer is associated with an immunosuppressive tumor microenvironment and can be selectively targeted via BET inhibition.

Role: Co-Investigator

Effort: 5%

R01 CA 226992 (Jani/Schuster) 05/01/2019-04/30/2024.

NIH NCI \$3.4M

Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer Outcomes

The results of this trial will be significant for the use of advanced molecular imaging to guide post-prostatectomy radiotherapy.

Role: Co-Investigator

Effort: 5%

%48889 (Harvey III) 01/01/19-12/31/19

Hematology/Oncology Pharmacy Association \$49,312

Phase II Evaluation of the Effect of 2 Versus 6 Hour Oxaliplatin Infusions on Neuropathy. This research is to support a hematology/oncology pharmacy practice research project with subsequent publication that aligns closely with the HOPA strategic plan to demonstrate the value of hematology/ oncology pharmacy practice.

Role: Co-Investigator

Effort: 5%

1 R01 CA228406-01A1 (Lesinski) 04/01/2019-03/30/2024

NIH \$253,094

Targeting immune stroma interactions in pancreatic cancer.

Testing the hypothesis that the tumor microenvironment represents a major barrier promoting immune suppression in pancreatic cancer, and that targeting Hsp90 can modulate components of the tumor microenvironment such as cytokines and signaling in T cells to enhance the efficacy of anti-PD-1 immunotherapy.

Role: Co-Investigator

Effort: 5%

COMPLETED GRANTS

1 R01 CA175316-01A1 (Kang) 04/01/14-02/28/19

NIH/NCI \$207,500

Transcription-dependent and -independent Signaling of RSK2 in Cancer Metastasis

In this proposal, we will examine the role of RSK2 as a signal integrator in metastatic cells by phosphorylating and regulating multiple protein factors to provide anti-apoptosis, pro-invasive and pro-metastatic signals in cancer cells, and validate RSK2 signaling pathways in combination with others as an alternative therapeutic target in treatment of metastatic cancers using a novel RSK inhibitor FMK-MEA.

Role: Co-Investigator

Effort: 5%

- 1 R21 MH108928-01 (Goodman) 01/01/16-12/31/18
NIH/NIMH \$150,000
PET Imaging Agents for 5-HT_{2C} Receptors
This project aims to satisfy this unmet need to develop carbon-11 5-HT_{2C}-specific radioligand antagonists with characteristics appropriate for in vivo imaging studies by PET.
Role: Co-Investigator
Effort: 5%
- 2017 Seed Grant (Shaib) 11/15/17-11/14/18
Hirshberg Foundation For Pancreatic Cancer \$40,000
Effect of Treatment of Immune Pathways in Pancreatic Adenocarcinoma: A Comparative
This is a tissue study of Pancreas cancer resected from patients. 50 patients received treatment prior to surgery and 50 patients did not receive treatments. We are comparing immune marker differences in these 2 groups.
Role: Co-Investigator
Effort: 2%
- 5 R01 CA 169188-04 (Jani) 09/01/12-06/30/18
NIH NCI \$328,840
Advance Molecular Imaging with FACBC PET-CT to Improve Post prostatectomy Radiotherapy
The results of this trial will be significant for the use of advanced molecular imaging to guide post-prostatectomy radiotherapy.
Role: Co-Investigator
Effort: 5%
- 2 R01 GM069971-09 (Morgan) 02/01/04-05/31/18
NIH/NIGMS \$316,710
Nitric Oxide Regulation of Human CYP Enzymes
We propose to use proteomic methods to define the scope of NO-mediated degradation in human hepatocytes. We will characterize the proteolytic enzymes involved in the NO-mediated degradation of CYP2B6 and 2C9, and elucidate the mechanism whereby NO regulates these processes in an enzyme-specific manner. This project will help us to understand how nitric oxide formed in the liver during inflammation contributes to this change, and so will allow us to predict what patients will need to have their drug doses adjusted to avoid this problem.
Role: Co-Investigator
Effort: 3%
- 4 R01 CA169937-04 (Mao) 04/15/13-03/31/18
NIH \$289,970
MR Investigation of IDH Mutation and Its Marker 2-HG in Brain Tumor Patients
We propose to develop a novel, non-invasive and clinically applicable(MRS) method for investigating a newly discovered onco-metabolite, R(-)-2-hydroxyglutarate (2-HG), that accompanies the progression of gliomas.

Role: Co-Investigator

Effort: 6%

640011-0615-04 (Qayed) 07/01/14-06/30/17

Children's Health Care of Atlanta (CHOA) \$92,104

A Phase I Study of Mesenchymal Stromal Cells for the Treatment of Acute and Chronic Graft versus Host Disease

The long-term goal of this project is to develop autologous mesenchymal stromal cells (MSC) as a cellular therapeutic to treat graft versus host disease (GVHD).

Role: Co-Investigator

Effort: 1%

(Sechopoulos) 08/16/13-08/30/17

Susan G. Komen Foundation \$186,440

Achieving Personalized Radiation Dose Estimates in Breast Cancer Screening

The objective of this research project is to develop, optimize, validate and test the methods necessary to obtain an accurate estimate of the personalized radiation dose each patient receives during breast cancer screening.

Role: Co-Investigator

Effort: 3%

1 R01 CA157754-01A1 (Nahta) 06/07/12-04/30/17

NIH/NCI \$207,500

Mechanisms of Herceptin Resistance

The long-term goal of this application is to identify new drug targets and predictors of Herceptin resistance in order to improve the survival of patients with HER2-overexpressing breast cancer.

Role: Co-Investigator

Effort: 3%

1 R01 CA160522-01A1 (Sun) 04/01/12-03/31/17

NIH \$207,500

Therapeutic potential of mTOR kinase inhibitors in lung cancer

This proposal will evaluate the therapeutic potential of novel mTOR kinase inhibitors either alone or in combination with other agents against lung cancer and determine the impact of genetic alterations on cell responses to these inhibitors.

Role: Co-Investigator

Effort: 5%

5 U01 CA168930-03 (Cummings) 08/23/12-06/30/17

NIH/NCI \$269,449

The Tumor Antigens Tn and SialylTn in Human Colorectal Carcinoma

The goal of this study is to propose, test and validate a new assay for colorectal carcinoma based on the Tn and SialylTn Antigens. Although there exist assays for early detection of other carcinomas, there is none for colorectal carcinoma and this would be the first of its kind.

Role: Co-Investigator

Effort: 7%

(Cox) 07/01/15-06/30/16
Radiological Society of North America \$40,000
MRI Liver Surface Nodularity Score: A New Noninvasive Biomarker for Chronic Viral
Role: Co-Investigator
Effort: 5%

1 R41 CA186498-01A1 (Kucuk) 09/01/15-08/31/16
NIH/NCI \$31,027
A Dietary Supplement as Adjunct Therapy in Castration-Resistant Prostate Cancer.
Role: Co-Investigator
Effort: 20%

1 R43 CA183312-01 (Chen) 05/01/14-04/30/15
Ocean Nanotech/NIH/NCI \$32,051
Assessment of Microvessel Density and Tumor Proximity for Prognosis of Cancer
The objective of this project is to develop a quantum dot (QD)-based imaging technology for
assessment of microvessel density and tumor proximity in order to provide an accurate
prognosis for cancer patients.
Role: Co-Investigator
Effort: 2%

(Goldsmith) 09/01/14-08/31/15
Children's Health Care of Atlanta (CHOA)
PHORG: A Phase I study using simvastatin in combination with conventional chemo
Phase I trial of simvastatin in combination with topotecan/cyclophosphamide or
vincristine/doxorubicin/dexrazoxane for refractory and/or relapsed solid tumors of childhood
to define toxicity and to evaluate cholesterol levels and IL6/STAT3 pathway change.
Role: Co-Investigator
Effort: 3.5%

5 R33 CA161873-02 (Chen & Hoyt) 07/27/11-06/30/15
NIH/NCI \$287,275
Developing a Platform for Prediction of Metastasis Using Multiplexed QD-imaging
This project proposes to develop a platform which combines imaging and quantification of
multiplexed immunostaining plus bioinformatics for the prediction of lymph node metastases
from the primary tumor of squamous cell carcinoma of the head and neck.
Role: Co-Investigator
Effort: 2%

5 P50 CA128301-04 (Meltzer) 09/28/07-08/31/14
NIH/NCI
Emory Molecular and Translational Imaging Center
The long term goal of this research is to determine if PET with anti-[18F] FACBC will lead
to improved patient care in the diagnosis and staging of prostate carcinoma and to elucidate
the mechanism of its uptake within malignant cells. A secondary goal is to translate this work

to facilitate the use of intensity-modulated-radiation-therapy (IMRT) for treatment of prostate carcinoma.

Role: Co-Investigator

Effort: 11%

(Chen)

09/28/12-09/27/14

Ocean Nanotech

MultiBiomarker Imaging Using Quantum Dots for Prediction of HPV-Associated Cancer

The objective of this project is to utilize QD technology for the prediction of HPV associated human cancer. Our team has extensive expertise in studies of HPV and cancer biomarkers.

We also have experience in using QD for imaging and quantification of biomarker expression in patient's tumor tissue specimens.

Role: Co-Investigator

Effort: 5%

CSOM230CUS18T (Owonikoko)

09/01/10-09/30/14

Novartis Pharmaceuticals Corporation

CSOM230CUS12T: A 3-Arm Randomized Phase II Trial Evaluating Single Agent and Combined Efficacy of Pasireotide and Everolimus in Adult Patients with Radiodine-Refractory Differentiated and Medullary Thyroid Cancer

The overall goal of this project is to evaluate single agent and combined efficacy of Pasireotide and Everolimus in adult patients with radiodine-refractory differentiated and medullary thyroid cancer.

Role: Co-Investigator

Effort: 5%

MORAB-009-003 (Owonikoko)

05/24/11-05/24/15

Morphotek

A Study of the Pattern of Expression of Alpha-Folate Receptors, Mesothelin, and Endosialin in Pleural Mesotheliomas

The overall goal of this project is to study the Pattern of Expression of Alpha-Folate Receptors, Mesothelin, and Endosialin in Pleural Mesotheliomas.

Role: Co-Investigator

Effort: 1%

CCOP SEED GRANT (Higgins)

03/01/13-02/28/14

Radiation Therapy Oncology Group

A Pilot Study of Soy Isoflavone in Combination with Radiation Therapy and Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

We hypothesize that soy isoflavone supplementation administered to patients with SCCHN undergoing concurrent modality therapy may decrease radiation-induced toxicity. We are asking for support for a pilot project examining the feasibility of supplementation of soy Isoflavones to patients with SCCHN undergoing concurrent chemoradiation.

Role: Co-Investigator

Effort: 1%

5 K23 EB013221-02(Tridandapani)

06/01/11-05/31/14

NIH

An Innovative Ultrasound-Based Prospective-Gating Technique for Cardiac CT

The objective of the proposed research is to merge the unique capabilities of ultrasound (US) and computed tomography (CT) by using real-time US information to provide a gating signal in order to obtain motion-free CT images of coronary arteries.

Role: Co-Investigator

Effort: 5%

5 P01 CA116676-03(Khuri)

06/20/06-05/31/11

NIH

Lung P01

Targeting Cell Signaling in Lung Cancer to Enhance Therapeutic Efficacy The overall goal is to develop effective clinical approaches to prevent, treat, and cure lung cancer.

Role: Co-Director of Biostatistics and Biomedical Informatics Core

Effort: 25%

5 R01 CA112643-05(Shin)

08/18/06-07/31/13

NIH

Second Primary Tumor Prevention with EGFR TKI'S and COX-2 Inhibitors in Head and Neck Cancer

The overall goal of this project is to study second primary tumor prevention using EGFR TKIs and COX-2 Inhibitors in head and neck cancer.

Role: Co-Investigator

Effort: 5%

5 P50 CA128613-05(Shin)

08/23/07-06/30/12

NIH

SPORE in Head and Neck

The goal of this proposal is to improve prevention and treatment of head and neck cancer with emphasis on new discoveries and rapid translation to patients who are suffering disability and morbidity caused by this disease.

Role: Co-Director of Biostatistics and Informatics Core

Effort: 25%

5 R01 CA116804-05(Van Meir)

09/01/07-07/31/12

NIH/NCI

Targeting Glioblastoma Using Novel Small Molecule HIF-1 Pathway Inhibitors

The overall goal of this project is to see if small molecules that inhibit the HIF-1 pathway will inhibit the growth of glioblastoma, either singly or in combination with other agents.

Role: Co-Investigator

Effort: 4%

R01 CA131294-01A2(Sharma)

07/01/09 - 12/31/10

Title of project: Role of Adipocytokines, Leptin and Adiponectin in Breast Carcinogenesis

Funding agency: NIH

Role: Co-Investigator.

Effort: 3%

K. BIBLIOGRAPHY**Statistics Methodology Peer-reviewed Publications**

1. Harvey RD, Zhang C, Lonial S, Kaufman JL, **Chen Z**. Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies. *Cancer*. 2019 (In Press)
2. **Chen Z**, Zheng Y, Wang Z, Kutner M, Curran WJ, Kowalski J. Interactive calculator for operating characteristics of phase I cancer clinical trials using standard 3+3 designs. *Contemporary Clinical Trials Communication*. 2018; 12:145-153.
3. **Chen Z**, Li Z, Zhuang R, Yuan Y, Kutner M, Owonikoko T, Curran WJ, Kowalski J. Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile. *PLoS One*. 2017; 12(1):e0170187.
4. **Chen Z**, Chen X. Exact Calculation of Minimum Sample Size for Estimating a Poisson Parameter. *Communications in Statistics – Theory and Methods*. 2016 45:16, 4692-4715.
5. **Chen Z**, Yuan Y, Li Z, Kutner M, Owonikoko TK, Curran W, Khuri F, Kowalski J. Dose Escalation with Over Dose and Under Dose Control for Phase I/II Clinical Trials. *Contemporary Clinical Trials*. 2015; 43:133-141.
6. **Chen Z**, Chen X. Rigorous Error Control Methods for Estimating Means of Bounded Random Variables. *Journal of Statistical Planning and Inference*. 2015; 157-158:54-76.
7. **Chen Z**, Cui Y, Owonikoko TK, Wang Z, Li Z, Luo R, Kutner M, Khuri F, Kowalski J. Escalation with Overdose Control using All Toxicities and Time to Event Toxicity Data in Cancer Phase I Clinical Trials. *Contemporary Clinical Trials*. 2014; 37(2):322-32.
8. **Chen Z**, Chen X. Exact Group Sequential Methods for Estimating a Binomial Proportion. *Journal of Probability and Statistics*. 2013; doi:10.1155/2013/603297.
9. **Chen Z**, Wang Z, Wang H, Owonikoko T, Kowalski J, Khuri F. Interactive Software “Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS[®])” for Cancer Phase I Clinical Trials. *The Open Medical Informatics Journal*. 2013; 7: 8-17.
10. Zhao Y, **Chen Z**, Huang X, Tighiouart M. Editorial: Adaptive and Sequential Methods for Clinical Trials. *Journal of Probability and Statistics*. 2013; doi:10.1155/2013/386058.
11. **Chen Z**, Tighiouart M, Kowalski J. Dose Escalation with Overdose Control using a Quasi-Continuous Toxicity Score in Cancer Phase I Clinical Trials. *Contemporary Clinical Trials*. 2012; 33(5):949-58.

12. Prajapati H, Spivey J, Hanish S, El-Rayes B, Kauh J, **Chen Z**, Kim HS. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). *Annals of Oncology*. 2013; 24(4):965-73.
13. **Chen Z**, Zhao Y, Cui Y, Kowalski J. Methodology and Application of Adaptive and Sequential Approaches in Contemporary Clinical Trials. *Journal of Probability and Statistics*. 2012; doi:10.1155/2012/527351.
14. Behera M, Fowler EE, Owonikoko TK, Land WH, Mayfield W, **Chen Z**, Khuri FR, Ramalingam SS, Heine JJ. Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung cancer data. *Biomedical Engineering Online*. 2011;10(1):97
15. **Chen Z**, Krailo MD, Azen SP, Tighiouart M. A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials. *Contemporary Clinical Trials*. 2010; 31(5):473-482.
16. Wang H, Bouzyk E, Kuehn A, Muller S, **Chen Z**, Khuri FR, Shin D, Rogatko A, Tighiouart M. caGrid-enabled caBIG™ silver level compatible head and neck cancer tissue database system. *The Open Medical Informatics Journal*. 2010; 4:171-178.
17. **Chen Z**, Krailo MD, Sun J, Azen SP. Range and trend of expected toxicity level (ETL) in standard A+B designs. *Contemporary Clinical Trials*. 2009; 30(2):123-8.
18. **Chen Z**, Wu AH, Gauderman J, Bernstein L, Ma H, Pike MC, Ursin G. Does mammographic density reflect ethnic differences in breast cancer incidence rates? *American Journal of Epidemiology* 2004; 159:140-147.

Collaborative Peer-reviewed Publications

19. Chen G, Park D, Magis AT, Behera M, Ramalingam SS, Owonikoko TK, Sica GL, Ye K, Zhang C, **Chen Z**, Curran WJ, Deng X. Mcl-1 interacts with Akt to promote lung cancer progression. *Cancer Res*. 2019; Oct 29.
20. Raggi P, Gadiyaram V, Zhang C, **Chen Z**, Lopaschuk G, Stillman AE. Statins Reduce Epicardial Adipose Tissue Attenuation Independent of Lipid Lowering: A Potential Pleiotropic Effect. *J Am Heart Assoc*. 2019; 8(12):e013104.
21. Shteamer JW, Harvey RD, Spektor B, Curseen K, Egan K, **Chen Z**, Gillespie TW, Sniecinski RM, Singh V. Safety of Intranasal Ketamine for Reducing Uncontrolled Cancer-Related Pain: Protocol of a Phase I/II Clinical Trial. *JMIR Res Protoc*. 2019; 8(4):e12125.
22. Mohamed A, Twardy B, Zordok MA, Ashraf K, Alkhoder A, Schrapp K, Steuer C, **Chen Z**, Pakkala S, Pillai R, Trad Wadsworth J, Higgins K, Beitler JJ, Ramalingam SS, Owonikoko TK, Khuri FR, Shin DM, Behera M, Saba NF. Concurrent chemoradiotherapy with weekly

- versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis. *Head Neck*. 2019; 41(5):1490-1498.
23. Owonikoko TK, Zhang G, Lallani SB, **Chen Z**, Martinson DE, Khuri FR, Lonial S, Marcus A, Sun SY. Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models. *PLoS One*. 2019; 14(2):e0206309.
 24. Saba NF, Force S, Staley C, Fernandez F, Willingham F, Pickens A, Cardona K, **Chen Z**, Goff L, Cardin D, Lambright E, Nesbitt J, Krasinskas A, Higgins K, Harvey RD, Owonikoko T, Ramalingam SS, Shin DM, Beitler JJ, El-Rayes BF, Salaria S, El-Rifai W, Landry J, Chakravarthy AB. Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer. *Am J Clin Oncol*. 2019; 42(4):331-336.
 25. Paplomata E, Zelnak A, Santa-Maria CA, Liu Y, Gogineni K, Li X, Moreno CS, **Chen Z**, Kaklamani V, O'Regan RM. Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer. *Clin Breast Cancer*. 2019; pii: S1526-8209(18)30637-2.
 26. Evans M, Baddour HM Jr, Magliocca KR, Müller S, Nannapaneni S, Chen AY, Kim S, **Chen Z**, Shin DM, Wang AY, Saba NF, Chen ZG. Prognostic implications of peritumoral vasculature in head and neck cancer. *Cancer Med*. 2019; 8(1):147-154.
 27. Piccinelli M, Cho SG, Garcia EV, Alexanderson E, Lee JM, Cooke CD, Goyal N, Sanchez MS, Folks RD, **Chen Z**, Votaw J, Koo BK, Bom HS. Vessel-specific quantification of absolute myocardial blood flow, myocardial flow reserve and relative flow reserve by means of fused dynamic $^{13}\text{NH}_3$ PET and CCTA: Ranges in a low-risk population and abnormality criteria. *J Nucl Cardiol*. 2018; doi: 10.1007/s12350-018-01472-3.
 28. Chehab S, Zhang C, Panjic EH, **Chen Z**, Kaufman JL, Lonial S, Nooka A, Harvey RD. Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites. *Cancer*. 2018; 124(22):4358-4365.
 29. Press RH, Morgan TM, Cutrell PK, Zhang C, **Chen Z**, Rahnema S, Sanda M, Pattaras J, Patel P, Jani AB, Rossi PJ. Patient-reported health-related quality of life outcomes after HDR brachytherapy between small (<60 cc) and large (≥ 60 cc) prostate glands. *Brachytherapy*. 2018. pii: S1538-4721 (18)30520-8.
 30. Lesinski GB, Nannapaneni S, Griffith CC, Patel M, Chen W, **Chen Z**, Ahmed R, Wieland A, Shin DM, Chen ZG, Saba NF. Interleukin-6/STAT3 Signaling is Prominent and Associated with Reduced Overall Survival in p16 Negative Oropharyngeal Squamous Cell Carcinoma. *Head Neck Pathol*. 2018 Sep 6.
 31. Rooney EG, Fleming MM, Patel JG, Clifford K, Kim C, **Chen Z**, Gillespie TW, Arciero CA, Subhedar PD. Are Lymph Node Characteristics on Axillary Ultrasound Associated with ≥ 3

- Positive Lymph Nodes in Patients Managed by the American College of Surgeons Oncology Group Z0011 Trial Criteria? *Am Surg.* 2018; 84(7):1133-1137.
32. Morgan TM, Press RH, Cutrell PK, Zhang C, **Chen Z**, Rahnema S, Jhaveri J, Sanda M, Pattaras J, Patel P, Jani AB, Rossi PJ. Hypofractionated external beam radiation therapy in combination with HDR boost for localized prostate cancer: patient reported quality of life outcomes. *J Contemp Brachytherapy.* 2018; 10(3):211-217.
 33. Owonikoko TK, Busari AK, Kim S, **Chen Z**, Akintayo A, Lewis C, Carthon BC, Alese OB, El-Rayes BF, Ramalingam SS, Harvey RD. Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials. *Oncology.* 2018; 95(3):138-146.
 34. Mohamed A, Twardy B, Zordok M, Ashraf K, Alkhoder A, Schrapp K, Steuer C, **Chen Z**, Pakkala S, Pillai R, Wadsworth T, Higgins K, Beitler J, Ramalingam S, Owonikoko T, Khuri F, Shin D, Behera M, Saba N. Concurrent chemoradiation with weekly versus tri-weekly cisplatin in locally advanced squamous cell carcinoma of the head and neck (SCCHN): A comparative analysis. *Head & Neck.* 2019; 41(5):1490-1498
 35. Cass AS, Alese JT, Kim C, Curry MA, LaFollette JA, **Chen Z**, Alese OB. Analysis of Opioid Use Following Curative Cancer Treatment at a Large Urban Safety-Net Hospital. *Clin J Pain.* 2018; 34(10):885-889.
 36. Kim HS, Shaib WL, Zhang C, Nagaraju GP, Wu C, Alese OB, **Chen Z**, Brutcher E, Renfroe M, El-Rayes BF. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. *Cancer.* 2018; 124(9):1992-2000.
 37. Wang P, Rahman MA, Zhao Z, Weiss K, Zhang C, **Chen Z**, Hurwitz SJ, Chen ZG, Shin DM, Ke Y. Visualization of the Cellular Uptake and Trafficking of DNA Origami Nanostructures in Cancer Cells. *J Am Chem Soc.* 2018; 140(7):2478-2484.
 38. Pokala SK, Zhang C, **Chen Z**, Gamboa AM, Cristofaro SL, Keilin SA, Cai Q, Willingham FF. Incidence, Survival, and Predictors of Lymph Node Involvement in Early-Stage Gastric Signet Ring Cell Carcinoma in the US. *J Gastrointest Surg.* 2018; 22(4):569-577. doi: 10.1007/s11605-017-3500-4.
 39. Pokala SK, Zhang C, **Chen Z**, Gamboa AM, Cristofaro SL, Keilin SA, Cai Q, Willingham FF. Lymph node metastasis in early gastric adenocarcinoma in the United States of America. *Endoscopy.* 2018; 50(5):479-486. doi: 10.1055/s-0043-122379.
 40. Wang X, Beitler JJ, Huang W, Chen G, Qian G, Magliocca KR, Patel MR, Chen AY, Zhang J, Nannapaneni S, Kim S, **Chen Z**, Deng X, Saba NF, Chen ZG, Arbiser J, Shin DM. Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin. *Clin Cancer Res.* 2018; 24(4):858-869.

41. Rahman MA, Wang P, Zhao Z, Wang D, Nannapaneni S, Zhang C, **Chen Z**, Griffith CC, Hurwitz SJ, Chen ZG, Ke Y, Shin DM. Systemic Delivery of Bc12-Targeting siRNA by DNA Nanoparticles Suppresses Cancer Cell Growth. *Angew Chem Int Ed Engl.* 2017; 56(50):16023-16027.
42. Zhang H, Kim S, **Chen Z**, Nannapaneni S, Chen AY, Moore CE, Sica G, Mosunjac M, Nguyen MLT, D'Souza G, Carey TE, Peterson LA, McHugh JB, Graham M, Komarck CM, Wolf GT, Walline HM, Bellile E, Riddell J 4th, Pai SI, Sidransky D, Westra WH, William WN Jr, Lee JJ, El-Naggar AK, Ferris RL, Seethala R, Grandis JR, Chen ZG, Saba NF, Shin DM; Head and Neck Cancer SPORE HIV supplement consortium. Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. *Head Neck.* 2017; 39(12):2433-2443.
43. Higgins KA, Pillai RN, **Chen Z**, Tian S, Zhang C, Patel P, Pakkala S, Shelton J, Force SD, Fernandez FG, Steuer CE, Owonikoko TK, Ramalingam SS, Bradley JD, Curran WJ. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study. *J Thorac Oncol.* 2017; 12(11):1687-1695.
44. Copur AS, Erik Everhart D, Zhang C, **Chen Z**, Shekhani H, Mathevossian S, Loveless J, Watson E, Kadri I, Wallace L, Simon E, Fulambarker AM. Effect of personality traits on adherence with positive airway pressure therapy in obstructive sleep apnea patients. *Sleep Breath.* 2018; 22(2):369-376. doi: 10.1007/s11325-017-1559-5.
45. Belalcazar A, Shaib WL, Farren MR, Zhang C, **Chen Z**, Yang L, Lesinski GB, El-Rayes BF, Nagaraju GP. Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells. *Cancer.* 2017; 123(24):4924-4933.
46. Nagaraju GP, Wu C, Merchant N, **Chen Z**, Lesinski GB, El-Rayes BF. Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer. *Cancer Lett.* 2017; 402:110-116. pii: S0304-3835(17)30357-9.
47. Nanda RH, Ganju RG, Schreiber E, **Chen Z**, Zhang C, Jegadeesh N, Cassidy R, Deng C, Eaton BR, Esiashvili N. Correlation of Acute and Late Brainstem Toxicities With Dose-Volume Data for Pediatric Patients With Posterior Fossa Malignancies. *Int J Radiat Oncol Biol Phys.* 2017; 98(2):360-366.
48. Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, Sica GL, Yu K, Koenig L, Patel NT, Behera M, Wu H, McCausland M, **Chen Z**, Zhang C, Khuri FR, Owonikoko TK, Ahmed R, Ramalingam SS. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. *Proc Natl Acad Sci USA.* 2017; 114(19):4993-4998.
49. Guo X, Koff JL, Moffitt AB, Cinar M, Ramachandiran S, **Chen Z**, Switchenko JM, Mosunjac M, Neill SG, Mann KP, Bagirov M, Du Y, Natkunam Y, Khoury HJ, Rossi MR, Harris W, Flowers CR, Lossos IS, Boise LH, Dave SS, Kowalski J, Bernal-Mizrachi L.

Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype. *Oncogene*. 2017; 36(29):4224-4232

50. Gilbert-Ross M, Konen J, Koo J, Shupe J, Robinson BS, Wiles WG 4th, Huang C, Martin WD, Behera M, Smith GH, Hill CE, Rossi MR, Sica GL, Rupji M, **Chen Z**, Kowalski J, Kasinski AL, Ramalingam SS, Fu H, Khuri FR, Zhou W, Marcus AI. Targeting adhesion signaling in *KRAS*, *LKB1* mutant lung adenocarcinoma. *JCI Insight*. 2017; 2(5):e90487.
51. Kong JH, Winton EF, Heffner LT, **Chen Z**, Langston AA, Hill B, Arellano M, El-Rassi F, Kim A, Jillella A, Kota VK, Bodó I, Khoury HJ. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia? *Cancer*. 2017; 123(13):2482-2488.
52. Anisuzzaman AS, Haque A, Wang D, Rahman MA, Zhang C, **Chen Z**, Chen ZG, Shin DM, Amin AR. *In Vitro* and *In Vivo* Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance. *Mol Cancer Ther*. 2017; 16(4):729-738.
53. Wilkinson S, Hou Y, Zoine JT, Saltz J, Zhang C, **Chen Z**, Cooper LA, Marcus AI. Coordinated cell motility is regulated by a combination of LKB1 farnesylation and kinase activity. *Sci Rep*. 2017; 7:40929
54. Nanda RH, Shehata BM, Khoshnam N, Durham M, Kim S, Selwanes W, **Chen Z**, Zhang C, Esiashvili N. Impact of lymph node evaluation in adjuvant and neoadjuvant chemotherapy settings on survival outcomes in Wilms tumour: a review of 185 cases from a single institution. *Pathology*. 2017; 49(1):19-23.
55. Schultz KA, Chen L, Kunin-Batson A, **Chen Z**, Woods WG, Gamis A, Kawashima T, Oeffinger KC, Nicholson HS, Neglia JP. Health-related Quality of Life (HR-QOL) and Chronic Health Conditions in Survivors of Childhood Acute Myeloid Leukemia (AML) with Down Syndrome (DS): A Report From the Children's Oncology Group. *J Pediatr Hematol Oncol*. 2017; 39(1):20-25.
56. Raphael KL, Chawla S, Kim S, Keith CG, Propp DR, **Chen ZN**, Woods KE, Keilin SA, Cai Q, Willingham FF. Pancreatic Insufficiency Secondary to Tobacco Exposure: A Controlled Cross-Sectional Evaluation. *Pancreas*. 2017; 46(2):237-243.
57. Akin-Akintayo OO, Jani AB, Odewole O, Tade FI, Nieh PT, Master VA, Bellamy LM, Halkar RK, Zhang C, **Chen Z**, Goodman MM, Schuster DM. Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer. *Clin Nucl Med*. 2017; 42(1):e22-e28.
58. Jani AB, Schreibmann E, Rossi PJ, Shelton J, Godette K, Nieh P, Master VA, Kucuk O, Goodman M, Halkar R, Cooper S, **Chen Z**, Schuster DM. Impact of ¹⁸F-Fluciclovine PET on Target Volume Definition for Postprostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial. *J Nucl Med*. 2017; 58(3):412-418.

59. Postlewait LM, Ethun CG, Kooby DA, Sarmiento JM, **Chen Z**, Staley CA 3rd, Brucher E, Adsay V, El-Rayes B, Maithel SK. Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial. *J Surg Oncol*. 2016; 114(3):336-41.
60. Shaib WL, Hawk N, Cassidy RJ, **Chen Z**, Zhang C, Brucher E, Kooby D, Maithel SK, Sarmiento JM, Landry J, El-Rayes BF. A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). *Int J Radiat Oncol Biol Phys*. 2016; 96(2):296-303.
61. Qian G, Wang D, Magliocca KR, Hu Z, Nannapaneni S, Kim S, **Chen Z**, Sun SY, Shin DM, Saba NF, Chen ZG. Human papillomavirus oncoprotein E6 upregulates c-Met through p53 downregulation. *Eur J Cancer*. 2016; 65:21-32.
62. DeFilipp Z, Rosand CB, Goldstein DA, Master VA, Carthon BC, Harris WB, Kucuk O, Al-Kadhimi Z, Cohen JB, Flowers CR, Lechowicz MJ, Nooka AK, Kaufman JL, Langston AA, **Chen Z**, Arora J, Waller EK. Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors. *Bone Marrow Transplant*. 2017; 52(1):132-134.
63. Wang D, Qian G, Zhang H, Magliocca KR, Nannapaneni S, Amin AR, Rossi M, Patel M, El-Deiry M, Wadsworth JT, **Chen Z**, Khuri FR, Shin DM, Saba NF, Chen ZG. HER3 targeting sensitizes HNSCC to cetuximab by reducing HER3 activity and HER2/HER3 dimerization - evidence from cell line and patient derived xenograft models. *Clin Cancer Res*. 2017; 23(3):677-686.
64. Hanna TN, Shekhani H, Maddu K, Zhang C, **Chen Z**, Johnson JO. Structured report compliance: effect on audio dictation time, report length, and total radiologist study time. *Emerg Radiol*. 2016; 23(5):449-53.
65. DeFilipp Z, Langston AA, **Chen Z**, Zhang C, Arellano ML, El Rassi F, Flowers CR, Kota VK, Al-Kadhimi Z, Veldman R, Jillella AP, Lonial S, Waller EK, Khoury HJ. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia? *Clin Lymphoma Myeloma Leuk*. 2016; 16(8):466-471.
66. Hu Z, Qian G, Müller S, Xu J, Saba NF, Kim S, **Chen Z**, Jiang N, Wang D, Zhang H, Lane K, Hoyt C, Shin DM, Chen ZG. Biomarker quantification by multiplexed quantum dot technology for predicting lymph node metastasis and prognosis in head and neck cancer. *Oncotarget*. 2016; 7(28):44676-44685.
67. Ditkofsky N, Shekhani HN, Cloutier M, **Chen ZN**, Zhang C, Hanna TN. Ionizing Radiation Knowledge Among Emergency Department Providers. *J Am Coll Radiol*. 2016; 13(9):1044-1049.

68. Owonikoko TK, Zhang G, Kim HS, Stinson RM, Bechara R, Zhang C, **Chen Z**, Saba NF, Pakkala S, Pillai R, Deng X, Sun SY, Rossi MR, Sica GL, Ramalingam SS, Khuri FR. Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. *J Transl Med*. 2016; 14(1):111.
69. Gamboa AM, Kim S, Force SD, Staley CA, Woods KE, Kooby DA, Maithel SK, Luke JA, Shaffer KM, Dacha S, Saba NF, Keilin SA, Cai Q, El-Rayes BF, **Chen Z**, Willingham FF. Treatment allocation in patients with early-stage esophageal adenocarcinoma: Prevalence and predictors of lymph node involvement. *Cancer*. 2016; 122(14):2150-7.
70. Ko SM, Zhang C, **Chen Z**, D'Marco L, Bellasi A, Stillman AE, Block G, Raggi P. Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium-based phosphate binders: a substudy of the Renegel in new dialysis trial. *J Nephrol*. 2016; 29(5):683-90.
71. Odewole OA, Tade FI, Nieh PT, Savir-Baruch B, Jani AB, Master VA, Rossi PJ, Halkar RK, Osunkoya AO, Akin-Akintayo O, Zhang C, **Chen Z**, Goodman MM, Schuster DM. Recurrent prostate cancer detection with anti-3-[¹⁸F]FACBC PET/CT: comparison with CT. *Eur J Nucl Med Mol Imaging*. 2016; 43(10):1773-83.
72. Zhang S, Gera L, Mamouni K, Li X, **Chen Z**, Kucuk O, Wu D. Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644, an aminobisphosphonate derivative. *Oncotarget*. 2016; 7(19):27489-98.
73. Chowdry RP, Sica GL, Kim S, **Chen Z**, Goodman A, Alexis D, Deng X, Owonikoko TK. Phosphorylated Bcl-2 and Mcl-1 as prognostic markers in small cell lung cancer. *Oncotarget*. 2016; DOI: 10.18632/oncotarget.7485.
74. Abugideiri M, Nanda RH, Butker C, Zhang C, Kim S, Chiang KY, Butker E, Khan MK, Haight AE, **Chen Z**, Esiashvili N. Factors Influencing Pulmonary Toxicity in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in the Setting of Total Body Irradiation-Based Myeloablative Conditioning. *Int J Radiat Oncol Biol Phys*. 2016; 94(2):349-59.
75. Kendi AT, Corey A, Magliocca KR, Galt JR, Zhang C, **Chen Z**, Higgins K, Beitler JJ, Wadsworth JT, El-Deiry MW, Schuster DM, Saba NF, Hudgins PA. Is there a role for PET/CT parameters to differentiate thyroid cartilage invasion from penetration? *Eur J Radiol*. 2016; 85(2):319-23.
76. Alese OB, Kim S, **Chen Z**, Ramalingam SS, Owonikoko TK, El-Rayes BF. Analysis of liver-directed therapies in U.S. cancer patients. *Curr Oncol*. 2015; 22(6):e457-61.
77. Patel KR, Burri SH, Asher AL, Crocker IR, Fraser RW, Zhang C, **Chen Z**, Kandula S, Zhong J, Press RH, Olson JJ, Oyesiku NM, Wait SD, Curran WJ, Shu HG, Prabhu RS. Comparing Preoperative With Postoperative Stereotactic Radiosurgery for Resectable Brain Metastases: A Multi-institutional Analysis. *Neurosurgery*. 2016; 79(2):279-85.

78. Qian G, Hu Z, Xu H, Müller S, Wang D, Zhang H, Kim S, **Chen Z**, Saba NF, Shin DM, Wang AY, Chen ZG. A novel prediction model for human papillomavirus-associated oropharyngeal squamous cell carcinoma using p16 and subcellular β -catenin expression. *J Oral Pathol Med*. 2016; 45(6):399-408.
79. Behera M, Ragin C, Kim S, Pillai RN, **Chen Z**, Steuer CE, Saba NF, Belani CP, Khuri FR, Ramalingam SS, Owonikoko TK. Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. *Cancer*. 2016; 122(1):50-60.
80. Patel BK, Shah NA, Galgano SJ, Newell M, Wang Z, **Chen Z**, D'Orsi CJ. Does Preoperative MRI Workup Affect Mastectomy Rates and/or Re-excision Rates in Patients with Newly Diagnosed Breast Carcinoma? A Retrospective Review. *Breast J*. 2015; 21(6):604-9.
81. Shaib WL, Goodman M, **Chen Z**, Kim S, Brucher E, Bekaii-Saab T, El-Rayes BF. Incidence and Survival of Appendiceal Mucinous Neoplasms: A SEER Analysis. *Am J Clin Oncol*. 2017; 40(6):569-573.
82. Meany HJ, Seibel NL, Krailo M, Villaluna D, **Chen Z**, Gaynon P, Neglia JP, Park JR, Hutchinson R, Sato JK, Wells RJ, Woods WG, Reaman G. Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group. *J Immunother*. 2015; 38(7):299-305.
83. Becker-Weidman D, Kalb B, Mittal PK, Harri PA, Arif-Tiwari H, Farris AB 3rd, **Chen Z**, Sungjin K, Martin DR. Differentiation of lipid-poor adrenal adenomas from non-adenomas with magnetic resonance imaging: Utility of dynamic, contrast enhancement and single-shot T2-weighted sequences. *Eur J Radiol*. 2015; 84(11):2045-51.
84. Behera M, Pillai RN, Owonikoko TK, Kim S, Steuer C, **Chen Z**, Saba NF, Belani CP, Khuri FR, Ramalingam SS. Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review. *J Thorac Oncol*. 2015; 10(8):1142-7.
85. Qian G, Jiang N, Wang D, Newman S, Kim S, **Chen Z**, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG, Saba NF. Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma. *Cancer*. 2015; 121(20):3600-11.
86. Shaib WL, Martin LK, Choi M, **Chen Z**, Krishna K, Kim S, Brucher E, Staley C 3rd, Maithel SK, Philip P, Abdel-Misih S, Bekaii-Saab TS, El-Rayes BF. Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery Improves Outcome in Patients With Primary Appendiceal Mucinous Adenocarcinoma: A Pooled Analysis From Three Tertiary Care Centers. *Oncologist*. 2015; 20(8):907-14.
87. Shaib W, Krishna K, Kim S, Goodman M, Rock J, **Chen Z**, Brucher E, Staley CI, Maithel SK, Abdel-Misih S, El-Rayes BF, Bekaii-Saab T. Appendiceal Neuroendocrine, Goblet and

Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome. *Cancer Res Treat.* 2016; 48(2):596-604.

88. Alese OB, El-Rayes BF, Sica G, Zhang G, Alexis D, La Rosa FG, Varella-Garcia M, **Chen Z**, Rossi MR, Adsay NV, Khuri FR, Owonikoko TK. Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. *Therapeutic Advances in Medical Oncology.* 2015; 7(2):56-62.
89. Alese OB, Kim S, **Chen Z**, Owonikoko TK, El-Rayes BF. Management patterns and predictors of mortality among US patients with cancer hospitalized for malignant bowel obstruction. *Cancer.* 2015; 121(11):1772-8.
90. Steuer CE, Behera M, Kim S, Patel N, **Chen Z**, Pillai R, Saba NF, Shin DM, Owonikoko TK, Khuri FR, Ramalingam SS. Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis. *Lung Cancer.* 2015; 88(1):80-4.
91. Xing M, Webber G, Prajapati HJ, **Chen Z**, El-Rayes B, Spivey JR, Pillai AA, Kim HS. Preservation of Quality of Life with Doxorubicin Drug Eluting Bead Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Longitudinal Prospective Study. *Journal of Gastroenterology and Hepatology.* 2015; 30(7):1167-74.
92. Owonikoko TK, Ramalingam SS, Miller DL, Force SD, Sica GL, Mendel J, **Chen Z**, Rogatko A, Tighiouart M, Harvey RD, Kim S, Saba NF, Pickens A, Behera M, Fu RW, Rossi MR, Auffermann WF, Torres WE, Bechara R, Deng X, Sun SY, Fu H, Gal AA, Khuri FR. A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer. *Clinical Cancer Research.* 2015; 21(8):1859-68
93. Colbert LE, Fisher SB, Balci S, Saka B, **Chen Z**, Kim S, El-Rayes BF, Adsay NV, Maithel SK, Landry JC, Curran WJ Jr. High Nuclear Hypoxia-Inducible Factor 1 Alpha Expression Is a Predictor of Distant Recurrence in Patients With Resected Pancreatic Adenocarcinoma. *International Journal of Radiation Oncology*Biophysics*Physics.* 2015; 91(3):631-9.
94. Prajapati HJ, Xing M, Spivey JR, Hanish SI, El-Rayes BF, Kauh JS, **Chen Z**, Kim HS. Survival, Efficacy, and Safety of Small Versus Large Doxorubicin Drug-Eluting Beads TACE Chemoembolization in Patients With Unresectable HCC. *AJR American journal of roentgenology.* 2014; 203(6):W706-14.
95. Barbee MS, Nooka A, Kaufman JL, Kim S, **Chen Z**, Heffner LT Jr, Lonial S, Harvey RD. Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients. *Cancer.* 2015;121(6):853-62.
96. Steuer CE, Behera M, Kim S, **Chen Z**, Saba NF, Pillai RN, Owonikoko TK, Khuri FR, Ramalingam SS. J Atypical Carcinoid Tumor of the Lung: a Surveillance, Epidemiology, and End Results Database Analysis. *Journal of Thoracic Oncology.* 2015;10(3):479-85.

97. Ramachandiran S, Adon A, Guo X, Wang Y, Wang H, **Chen Z**, Kowalski J, Sunay UR, Young AN, Brown T, Mar JC, Du Y, Fu H, Mann KP, Natkunam Y, Boise LH, Saavedra HI, Lossos IS, Bernal-Mizrachi L. Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF- κ B pathway. *International Journal of Cancer*. 2015; 136(10):2341-51.
98. Odewole OA, Oyenuga OA, Tade F, Savir-Baruch B, Nieh PT, Master V, **Chen Z**, Wang X, Jani AB, Bellamy LM, Halkar RK, Goodman MM, Schuster DM. Reproducibility and Reliability of Anti-3-[18 F]FACBC Uptake Measurements in Background Structures and Malignant Lesions on Follow-Up PET-CT in Prostate Carcinoma: an Exploratory Analysis. *Molecular Imaging Biology*. 2015;17(2):277-83.
99. Hu Z, Müller S, Qian G, Xu J, Kim S, **Chen Z**, Jiang N, Wang D, Zhang H, Saba NF, Shin DM, Chen ZG. Human papillomavirus 16 oncoprotein regulates the translocation of β -catenin via the activation of epidermal growth factor receptor. *Cancer*. 2015; 121(2):214-25.
100. Owonikoko TK, Zhang G, Deng X, Rossi MR, Switchenko JM, Doho GH, **Chen Z**, Kim S, Strychor S, Christner SM, Beumer J, Li C, Yue P, Chen A, Sica GL, Ramalingam SS, Kowalski J, Khuri FR, Sun SY. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. *Cancer Medicine*. 2014; 3(6):1579-94.
101. Saba NF, Hurwitz SJ, Magliocca K, Kim S, Owonikoko TK, Harvey D, Ramalingam SS, **Chen Z**, Rogerio J, Mendel J, Kono SA, Lewis C, Chen AY, Higgins K, El-Deiry M, Wadsworth T, Beitler JJ, Shin DM, Sun SY, Khuri FR. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/ metastatic squamous cell carcinoma of the head and neck. *Cancer*. 2014; 120(24):3940-51.
102. Yang X, Tridandapani S, Beitler JJ, Yu DS, **Chen Z**, Kim S, Bruner DW, Curran WJ, Liu T. Diagnostic Accuracy of Ultrasonic Histogram Features to Evaluate Radiation Toxicity of the Parotid Glands: A Clinical Study of Xerostomia Following Head-and-Neck Cancer Radiotherapy. *Academic Radiology*. 2014; 21(10):1304-13.
103. Behera M, Owonikoko TK, Kim S, **Chen Z**, Higgins K, Ramalingam SS, Shin DM, Khuri FR, Beitler JJ, Saba NF. Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a systematic review. *Oral Oncology*. 2014; 50(9):888-94.
104. Wang D, Fei B, Halig LV, Qin X, Hu Z, Xu H, Wang YA, **Chen Z**, Kim S, Shin DM, Chen ZG. Targeted iron-oxide nanoparticle for photodynamic therapy and imaging of head and neck cancer. *ACS Nano*. 2014; 8(7):6620-32.
105. Jiang N, Wang D, Hu Z, Shin HJ, Qian G, Rahman MA, Zhang H, Amin AR, Nannapaneni S, Wang X, **Chen Z**, Garcia G, Macbeath G, Shin DM, Khuri FR, Ma J, Chen ZG, Saba N. Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab

- Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma (HNSCC). *Molecular Cancer Therapy*. 2014;13(7):1826-36.
106. Boddu SR, Corey A, Peterson R, Saindane AM, Hudgins PA, **Chen Z**, Wang X, Applegate KE. Fluoroscopic-guided lumbar puncture: fluoroscopic time and implications of body mass index--a baseline study. *AJNR Am J Neuroradiol*. 2014;35(8):1475-80.
 107. Hawk NN, Long TE, Imam MH, Mathew BM, Kim S, **Chen Z**, Goodman M, Sullivan P, Brutcher E, Kauh J, Maithel SK, Adsay VN, Farris AB, Staley C, El-Rayes BF. Clinicopathologic Features and Outcome of Young Adults With Stage IV Colorectal Cancer. *American Journal of Clinical Oncology*. 2015; 38(6):543-9.
 108. Ragin C, Obikoya-Malomo M, Kim S, **Chen Z**, Flores-Obando R, Gibbs D, Koriyama C, Aguayo F, Koshiol J, Caporaso NE, Carpagnano GE, Ciotti M, Dosaka-Akita H, Fukayama M, Goto A, Spandidos DA, Gorgoulis V, Heideman DA, van Boerdonk RA, Hiroshima K, Iwakawa R, Kastrinakis NG, Kinoshita I, Akiba S, Landi MT, Eugene Liu H, Wang JL, Mehra R, Khuri FR, Lim WT, Owonikoko TK, Ramalingam S, Sarchianaki E, Syrjanen K, Tsao MS, Sykes J, Hee SW, Yokota J, Zaravinos A, Taioli E. HPV-associated lung cancers: an international pooled analysis. *Carcinogenesis*. 2014;35(6):1267-75.
 109. Majumdar D, Jung KH, Zhang H, Nannapaneni S, Wang X, Amin AR, **Chen Z**, Chen ZG, Shin DM. Luteolin nanoparticle in chemoprevention: in vitro and in vivo anticancer activity. *Cancer Prevention Research (Phila)*. 2014;7(1):65-73.
 110. Wang Y, Zhang S, Iqbal S, **Chen Z**, Wang X, Wang YA, Liu D, Bai K, Ritenour C, Kucuk O, Wu D. Pomegranate extract inhibits the bone metastatic growth of human prostate cancer cells and enhances the in vivo efficacy of docetaxel chemotherapy. *Prostate*. 2014; 74(5):497-508.
 111. Shaib WL, Sharma R, Brutcher E, Kim S, Maithel SK, **Chen Z**, Kooby DA, Kauh J, Landry J, El-Rayes BF. Treatment utilization and surgical outcome of ampullary and duodenal adenocarcinoma. *Journal of Surgical Oncology*. 2014;109(6):556-60
 112. Donnelly SM, Paplomata E, Peake BM, Sanabria E, **Chen Z**, Nahta R. P38 MAPK contributes to resistance and invasiveness of HER2- overexpressing breast cancer. *Curr Med Chem*. 2014; 21(4):501-10.
 113. Schultz KA, Chen L, **Chen Z**, Kawashima T, Oeffinger KC, Woods WG, Nicholson HS, Neglia JP. Health conditions and quality of life in survivors of childhood acute myeloid leukemia comparing post remission chemotherapy to BMT: a report from the children's oncology group. *Pediatric Blood Cancer*. 2014;61(4):729-36.
 114. Dey N, Barwick BG, Moreno CS, Ordanic-Kodani M, **Chen Z**, Oprea-Ilies G, Tang W, Catzavelos C, Kerstann KF, Sledge GW Jr, Abramovitz M, Bouzyk M, De P, Leyland-Jones BR. Wnt signaling in triple negative breast cancer is associated with metastasis. *BMC Cancer*. 2013; 13(1):537.

115. Owonikoko TK, Chowdry RP, **Chen Z**, Kim S, Saba NF, Shin DM, Khuri FR. Clinical Efficacy of Targeted Biologic Agents as Second-Line Therapy of Advanced Thyroid Cancer. *Oncologist*. 2013;18(12):1262-9.
116. Mahaseth H, Brutcher E, Kauh J, Hawk N, Kim S, **Chen Z**, Kooby DA, Maithel SK, Landry J, El-Rayes BF. Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma. *Pancreas*. 2013; 42(8):1311-5.
117. Saba N, Hurwitz SJ, Kono S, Yang CS, Zhao Y, **Chen Z**, Sica GL, Muller S, Moreno-Williams R, Lewis M, Grist W, Chen AY, Moore CE, Owonikoko TK, Ramalingam SS, Beitler JJ, Nannapaneni S, Shin HJ, Grandis JR, Khuri FR, Chen ZG, Shin DM. Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase 1b and Pharmacokinetic Study. *Cancer Prevention Research (Phila)*. 2014; 7(3):283-91.
118. Zhang S, Wang Y, **Chen Z**, Kim S, Iqbal S, Chi A, Ritenour C, Wang YA, Kucuk O, Wu D. Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells. *Prostate*. 2013; 73(15):1681-9.
119. Eaton BR, Kim S, Marcus DM, Prabhu R, **Chen Z**, Ramalingam SS, Curran WJ Jr, Higgins KA. Effect of prophylactic cranial irradiation on survival in elderly patients with limited-stage small cell lung cancer. *Cancer*. 2013; 119(21):3753-60.
120. D'Marco LG, Bellasi A, Kim S, **Chen Z**, Block GA, Raggi P. Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renagel in New Dialysis trial. *Nephrology, Dialysis, Transplantation*. 2013; 28(10):2586-95.
121. Tang H, Hua F, Wang J, Sayeed I, Wang X, **Chen Z**, Yousuf S, Atif F, Stein DG. Progesterone and vitamin D: improvement after traumatic brain injury in middle-aged rats. *Hormones and Behavior*. 2013; 64(3):527-38.
122. Saba NF, Magliocca KR, Kim S, Muller S, **Chen Z**, Owonikoko TK, Sarlis NJ, Eggers C, Phelan V, Grist WJ, Chen AY, Ramalingam SS, Chen ZG, Beitler JJ, Shin DM, Khuri FR, Marcus AI. Acetylated Tubulin (AT) as a Prognostic Marker in Squamous Cell Carcinoma of the Head and Neck. *Head Neck Pathology*. 2014;8(1):66-72.
123. Tarbell NJ, Friedman H, Polkinghorn WR, Yock T, Zhou T, **Chen Z**, Burger P, Barnes P, Kun L. High-Risk Medulloblastoma: A Pediatric Oncology Group Randomized Trial of Chemotherapy Before or After Radiation Therapy (POG 9031). *Journal of Clinical Oncology*. 2013; 31(23):2936-41.
124. Kalb B, Martin DR, Sarmiento JM, Erickson SH, Gober D, Tapper EB, **Chen Z**, Adsay NV. Paraduodenal Pancreatitis: Clinical Performance of MR Imaging in Distinguishing from Carcinoma. *Radiology*. 2013; 269(2):475-81.

125. Rahman MA, Amin AR, Wang D, Koenig L, Nannapaneni S, **Chen Z**, Wang Z, Sica G, Deng X, Chen ZG, Shin DM. RRM2 Regulates Bcl-2 in Head and Neck and Lung Cancers: A Potential Target for Cancer Therapy. *Clinical Cancer Research*. 2013; 19(13):3416-28.
126. Owonikoko TK, Ragin C, **Chen Z**, Kim S, Behera M, Brandes JC, Saba NF, Pentz R, Ramalingam SS, Khuri FR. Real-World Effectiveness of Systemic Agents Approved for Advanced Non-Small Cell Lung Cancer: A SEER-Medicare Analysis. *Oncologist*. 2013; 18(5):600-10.
127. Saindane AM, Lim PP, Aiken A, **Chen Z**, Hudgins PA. Factors determining the clinical significance of an "empty" sella turcica. *AJR American Journal of Roentgenology*. 2013; 200(5):1125-31.
128. Amzat R, Taleghani P, Miller DL, Beitler JJ, Bellamy LM, Nye JA, Yu W, Savir-Baruch B, Osunkoya AO, **Chen Z**, Auffermann WF, Goodman MM, Schuster DM. Pilot Study of the Utility of the Synthetic PET Amino-Acid Radiotracer Anti-1-Amino-3-[¹⁸F]Fluorocyclobutane-1-Carboxylic Acid for the Noninvasive Imaging of Pulmonary Lesions. *Molecular Imaging and Biology*. 2013; 15(5):633-43.
129. Webber GR, Baumgarten DA, **Chen Z**, Wang Z, Mullins ME. A Survey of Diagnostic Radiology Residency Program Directors and the Increasing Demands of Program Leadership. *Journal of the American College of Radiology*. 2013; 10(7):523-6.
130. Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, **Chen Z**, Wang X, Jiang K, Nastoupil LJ, Khan MK. Patterns of Failure in Advanced Stage Diffuse Large B-cell Lymphoma Patients After Complete Response to R-CHOP Immunochemotherapy and the Emerging Role of Consolidative Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*. 2013; 86(3):569-77.
131. Alexopoulos N, Melek BH, Arepalli CD, Hartlage GR, **Chen Z**, Kim S, Stillman AE, Raggi P. Effect of Intensive Versus Moderate Lipid-Lowering Therapy on Epicardial Adipose Tissue in Hyperlipidemic Post-Menopausal Women: A Substudy of the BELLES Trial (Beyond Endorsed Lipid Lowering with EBT Scanning). *Journal of the American College of Cardiology*. 2013; 61(19):1956-61.
132. Moreno CC, Pinho D, Nelson RC, Sahani DV, Jenkins M, Zabrycki M, Chaudhry H, Kang J, **Chen Z**. Lessons learned from 118,970 multidetector computed tomographic intravenous contrast material administrations: impact of catheter dwell time and gauge, catheter location, rate of contrast material administration, and patient age and sex on volume of extravasate. *Journal of Computer Assisted Tomography*. 2013; 37(2):286-8.
133. Harvey RD, Owonikoko TK, Lewis CM, Akintayo A, **Chen Z**, Tighiouart M, Ramalingam SS, Fanucchi MP, Nadella P, Rogatko A, Shin DM, El-Rayes B, Khuri FR, Kauh JS. A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. *British Journal of Cancer*. 2013; 108(4):762-5.

134. Shin DM, Zhang H, Saba NF, Chen AY, Nannapaneni S, Amin AR, Müller S, Lewis M, Sica G, Kono S, Brandes JC, Grist WJ, Moreno-Williams R, Beitler JJ, Thomas SM, **Chen Z**, Shin HJ, Grandis JR, Khuri FR, Chen ZG. Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies. *Clinical Cancer Research*. 2013; 19(5):1244-56.
135. Ramalingam SS, Owonikoko TK, Behera M, Subramanian J, Saba NF, Kono SA, Gal AA, Sica G, Harvey RD, **Chen Z**, Klass CM, Shin DM, Fu H, Sun SY, Govindan R, Khuri FR. Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non-Small-Cell Lung Cancer. *Journal of Thoracic Oncology*. 2013; 8(3):369-72.
136. Prajapati H, Dhanasekaran R, Hanish S, El-Rayes B, Kauh J, Maithel S, **Chen Z**, Kim HS. Safety and Efficacy of Doxorubicin Drug-eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma. *Journal of Vascular and Interventional Radiology*. 2013; 24(3):307-15.
137. Schuster DM, Taleghani PA, Nieh PT, Master VA, Amzat R, Savir-Baruch B, Halkar RK, Fox T, Osunkoya AO, Moreno CS, Nye JA, Yu W, Fei B, Wang Z, **Chen Z**, Goodman MM. Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] - fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake. *American Journal of Nuclear Medicine Molecular Imaging*. 2013; 3(1):85-96.
138. Owonikoko TK, Hossain MS, Bhimani C, **Chen Z**, Kim S, Ramalingam SS, Sun SY, Shin DM, Waller EK, Khuri FR. Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer. *Cancer*. 2013; 119(8):1503-11.
139. Eaton BR, McDonald MW, Kim S, Marcus RB Jr, Sutter AL, **Chen Z**, Esiashvili N. Radiation therapy target volume reduction in pediatric rhabdomyosarcoma: Implications for patterns of disease recurrence and overall survival. *Cancer*. 2013; 119(8):1578-85.
140. Zhang S, Wang X, Iqbal S, Wang Y, Osunkoya AO, **Chen Z**, Chen Z, Shin DM, Yuan H, Wang YA, Zhou HE, Chung LW, Ritenour C, Kucuk O, Wu D. Epidermal growth factor promotes protein degradation of epithelial protein lost in neoplasm (EPLIN), a putative metastasis suppressor, during epithelial-mesenchymal transition. *Journal of Biological Chemistry*. 2012; 288(3):1469-79.
141. Stapleford L, Landry J, Schreiber E, Waller A, Pan L, Kim S, **Chen Z**, Crocker I, Fox T, Quantitative Analysis of Pre- and Post-treatment PET-CT Scans using Deformable Image Registration Methods. *Journal of Radiosurgery and SBRT*. 2012; 2(1):51-62.
142. Yin S, Kaluz S, Devi NS, Jabbar AA, de Noronha RG, Mun J, Zhang Z, Boreddy PR, Wang W, Wang Z, Abbruscato T, **Chen Z**, Olson JJ, Zhang R, Goodman M, Nicolaou KC, Van Meir EG. Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with

- HIF signaling by disrupting HIF-1 α interaction with co-factors p300/CBP. *Clinical Cancer Research*. 2012; 18(24):6623-6633.
143. Wang D, Müller S, Amin AR, Huang D, Su L, Hu Z, Rahman MA, Nannapaneni S, Koenig L, **Chen Z**, Tighiouart M, Shin DM, Chen ZG. The Pivotal Role of Integrin β 1 in Metastasis of Head and Neck Squamous Cell Carcinoma. *Clinical Cancer Research*. 2012; 18(17):4589-99.
 144. Sun X, Li J, Sica G, Fan SQ, Wang Y, **Chen Z**, Muller S, Chen ZG, Fu X, Dong XY, Guo P, Shin DM, Dong JT. Interruption of nuclear localization of ATBF1 during the histopathologic progression of head and neck squamous cell carcinoma. *Head Neck* 2013; 35(7):1007-14.
 145. Muringampurath-John D, Jaye DL, Flowers CR, Saxe D, **Chen Z**, Lechowicz MJ, Weisenburger DD, Bast M, Arellano ML, Bernal-Mizrachi L, Heffner LT, McLemore M, Kaufman JL, Winton EF, Lonial S, Armitage JO, Khoury HJ. Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. *British Journal of Haematology*. 2012; 158(5):608-14.
 146. Owonikoko TK, Behera M, **Chen Z**, Bhimani C, Curran WJ, Khuri FR, Ramalingam SS. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. *Journal of Thoracic Oncology*. 2012; 7(5):866-72.
 147. Tigges S, Arepalli CD, Tridandapani S, Oshinski J, Kurz CR, Richer EJ, **Chen Z**, Stillman AE, Raggi P. A phantom study of the effect of heart rate, coronary artery displacement and vessel trajectory on coronary artery calcium score: Potential for risk misclassification. *Journal of Cardiovascular Computed Tomography*. 2012; 6(4):260-7.
 148. Sun X, Fu X, Li J, Xing C, Martin DW, Zhang HH, **Chen Z**, Dong JT. Heterozygous deletion of Atbf1 by the Cre-loxP system in mice causes preweaning mortality. *Genesis*. 2012; 50(11):819-27.
 149. Behera M, Owonikoko TK, **Chen Z**, Kono SA, Khuri FR, Belani CP, Ramalingam SS. Single agent maintenance therapy for advanced stage non-small cell lung cancer: A meta-analysis. *Lung Cancer* 2012; 77(2):331-8.
 150. Arellano M, Pakkala S, Langston A, Tighiouart M, Pan L, **Chen Z**, Heffner LT, Lonial S, Winton E, Khoury HJ. Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia. *Cancer*. 2012; 118(21):5278-82.
 151. Pentz RD, Harvey RD, White M, Farmer ZL, Dashevskaya O, **Chen Z**, Lewis C, Owonikoko TK, Khuri FR. Research biopsies in phase I studies: views and perspectives of participants and investigators. *IRB*. 2012; 34(2):1-8.

152. Webber GR, Mullins ME, **Chen Z**, Meltzer CC. Administrative organization in diagnostic radiology residency program leadership. *Journal of the American College of Radiology*. 2012; 9(4):275-8.
153. Kalb B, Sharma P, Tigges S, Ray GL, Kitajima HD, Costello JR, **Chen Z**, Martin DR. MR Imaging of Pulmonary Embolism: Diagnostic Accuracy of Contrast-enhanced 3D MR Pulmonary Angiography, Contrast-enhanced Low-Flip Angle 3D GRE, and Nonenhanced Free-Induction FISP Sequences. *Radiology*. 2012; 263(1):271-278
154. Rahman MA, Amin AR, Wang X, Zuckerman JE, Choi CH, Zhou B, Wang D, Nannapaneni S, Koenig L, **Chen Z**, Chen ZG, Yen Y, Davis ME, Shin DM. Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. *Journal of Controlled Release*. 2012; 159(3):384-92.
155. Xu J, Müller S, Nannapaneni S, Pan L, Wang Y, Peng X, Wang D, Tighiouart M, **Chen Z**, Saba NF, Beitler JJ, Shin DM, Chen ZG. Comparison of quantum dot technology with conventional immunohistochemistry in examining aldehyde dehydrogenase 1A1 as a potential biomarker for lymph node metastasis of head and neck cancer. *European Journal of Cancer*. 2012; 48(11):1682-91.
156. Pierre-Jerome C, Reyes EJ, Moncayo V, **Chen ZN**, Terk MR. MRI of the cuboid bone: Analysis of changes in diabetic versus non-diabetic patients and their clinical significance. *European Journal of Radiology*. 2011; 81(10):2771-5.
157. Peng XH, Wang Y, Huang D, Wang Y, Shin HJ, **Chen Z**, Spewak MB, Mao H, Wang X, Wang Y, Chen ZG, Nie S, Shin DM. Targeted Delivery of Cisplatin to Lung Cancer Using ScFvEGFR-Heparin-Cisplatin Nanoparticles. *ACS Nano*. 2011; 5(12):9480-93.
158. Becker-Weidman DJ, Kalb B, Sharma P, Kitajima HD, Lurie CR, **Chen Z**, Spivey JR, Knechtle SJ, Hanish SI, Adsay NV, Farris AB 3rd, Martin DR. Hepatocellular Carcinoma Lesion Characterization: Single-Institution Clinical Performance Review of Multiphase Gadolinium-enhanced MR Imaging--Comparison to Prior Same-Center Results after MR Systems Improvements. *Radiology*. 2011; 261(3):824-33.
159. Muringampurath-John D, Flowers CR, Toscano M, **Chen Z**, Kaufmann J, Arellano M, Bernal-Mizrachi L, Heffner LT, Lechowicz MJ, McLemore M, Winton E, Jaye DL, Lonial S, Jean Khoury H. Rituximab-HyperCVAD for aggressive Non-Hodgkin's Lymphoma. *Leukemia and Lymphoma*. 2012; 53(4):725-7.
160. Pakkala S, **Chen Z**, Rimland D, Owonikoko TK, Gunthel C, Brandes JR, Saba NR, Shin DM, Curran WJ, Fadlo R, Khuri FR, Ramalingam S. HIV-Associated Lung Cancer in the Era of Highly Active Antiretroviral Therapy (HAART). *Cancer*. 2011; 118(1):164-72.
161. Arellano M, Bernal-Mizrachi L, Pan L, Tighiouart M, Souza L, Guo X, McLemore M, Lima L, Sunay S, Heffner LT, **Chen Z**, Chen GZ, Langston A, Winton E, Khoury J.

- Significance of Leukopenia at the Time of Diagnosis in Acute Myeloid Leukemia. *Clinical Lymphoma, Myeloma & Leukemia*. 2011; 11(5):427-32.
162. Zhang S, Wang X, Osunkoya AO, Iqbal S, Wang Y, Chen Z, Müller S, **Chen Z**, Jossen S, Coleman IM, Nelson PS, Wang YA, Wang R, Shin DM, Marshall FF, Kucuk O, Chung LW, Zhau HE, Wu D. EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis. *Oncogene*. 2011; 30(50):4941-52.
163. Gilman AL, Schultz KR, Goldman F, Sale G, Krailo MD, **Chen Z**, Langholz B, Jacobsohn D, Chan KW, Ryan R, Kellick M, Neudorf S, Godder K, Sandler E, Sahdev I, Grupp S, Sanders J, Wall DA. Randomized Trial of Hydroxychloroquine for Newly-diagnosed Chronic Graft-versus-Host Disease in Children: A Children's Oncology Group Study. *Biology Blood Marrow Transplant*. 2011; 18(1):84-91.
164. Yoshida EJ, Chen H, Torres M, Andic F, Liu HY, **Chen Z**, Sun X, Curran WJ, Liu T. Reliability of Quantitative Ultrasonic Assessment of Normal-Tissue Toxicity In Breast Cancer Radiotherapy. *International Journal of Radiation Oncology, Biology, Physics*. 2011; 82(2):724-31.
165. Webber GR, Mullins ME, **Chen Z**, Meltzer CC. What's in a Name? US Academic Radiology Departments: Investigation of the Frequency of and Associated Factors in Nontraditional Department Titles. *Journal of the American College of Radiology*. 2011; 8(3):186-90.
166. Edgerton N, Sirintrapun J, Munoz M, **Chen Z**, Osunkoya A. Micropapillary Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic Analysis of 24 Cases. *International Journal of Urology*. 2011; 18(1):49-54.
167. Oliva IV, Smith SL, **Chen Z**, Osunkoya AO. Urothelial carcinoma of the bladder with transmural and direct prostatic stromal invasion: does extent of stromal invasion significantly impact patient outcome? *Human Pathology*. 2011; 42(1):51-6.
168. Pappo AS, Krailo M, **Chen Z**, Rodriguez-Galindo C, Reaman GH. The Infrequent Tumor Initiative of the Children's Oncology Group (COG): Initial lessons learned and their impact on future plans. *Journal of Clinical Oncology*. 2010; 28(33):5011-5016.
169. Vogt AP, **Chen Z**, Osunkoya AO. Rete testis invasion by malignant germ cell tumor and/or intratubular germ cell neoplasia: what is the significance of this finding? *Human Pathology*. 2010; 1(9):1339-44.
170. Janik M, Hartlage G, Alexopoulos N, Mirzoyev Z, McLean DS, Arepalli CD, **Chen Z**, Stillman AE, Raggi P. Epicardial adipose tissue volume and coronary artery calcium to predict myocardial ischemia on positron emission tomography-computed tomography studies. *Journal of Nuclear Cardiology*. 2010; 17(5):841-7.

171. Zhang S, Zhou HE, Osunkoya AO, Iqbal S, Yang X, Fan S, **Chen Z**, Wang R, Marshall FF, Chung LW, Wu D. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. *Molecular Cancer*. 2010; 9(1):9.
172. Schultz KA, Chen L, **Chen Z**, Zeltzer LK, Nicholson S, Neglia JP. Health and risk behaviors in survivors of childhood acute myeloid leukemia: a report from the Children's Oncology Group. *Pediatrics Blood & Cancer*. 2010; 55(1):157-64.
173. Beaty O 3rd, Berg S, Blaney S, Malogolowkin M, Krailo M, Knight R, Schaiquevich P, Stewart C, **Chen Z**, Nelson M, Voss S, Ivy SP, Adamson PC. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study. *Pediatrics Blood & Cancer*. 2010; 55(3):440-5.
174. Katzenstein HM, Chang KW, Krailo M, **Chen Z**, Finegold MJ, Rowland J, Reynolds M, Pappo A, London WB, Malogolowkin M. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group. *Cancer*. 2009; 115(24):5828-5835.
175. Chou AJ, Kleinerman ES, Krailo MD, **Chen Z**, Betcher DL, Healey JH, Conrad EU 3rd, Nieder ML, Weiner MA, Wells RJ, Womer RB, Meyers PA. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. *Cancer*. 2009; 115(22):5339-48.
176. Meyers RL, Rowland JR, Krailo M, **Chen Z**, Katzenstein HM, Malogolowkin MH. Predictive power of pretreatment prognostic factors in children with hepatoblastoma: A report from the Children's Oncology Group. *Pediatric Blood & Cancer*. 2009; 53(6):1016-22.
177. Dubois SG, Krailo MD, Lessnick SL, Smith R, **Chen Z**, Marina N, Grier HE, Stegmaier K. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: A report from the Children's Oncology Group. *Pediatric Blood & Cancer*. 2008; 52(3):324-327.
178. Goldsby R, Burke C, Nagarajan R, Zhou T, **Chen Z**, Marina N, Friedman D, Neglia J, Chuba P, Bhatia S. Second solid malignancies among children, adolescents, and young adults diagnosed with malignant bone tumors after 1976: follow-up of a children's oncology group cohort. *Cancer*. 2008; 113(9):2597-604.
179. Leavey PJ, Mascarenhas L, Marina N, **Chen Z**, Krailo M, Miser J, Brown K, Tarbell N, Bernstein ML, Granowetter L, Gebhardt M, Grier HE. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. *Pediatric Blood & Cancer* 2008; 51(3):334-8.
180. Lee E, McKean-Cowdin R, Ma H, **Chen Z**, Van Den Berg D, Henderson BE, Bernstein L, Ursin G. Evaluation of unclassified variants in the breast cancer susceptibility genes

- BRCA1 and BRCA2 using five methods: results from a population-based study of young breast cancer patients. *Breast Cancer Research*. 2008; 10(1):R19.
181. Fujii H, Cuvelier G, She K, Aslanian S, Shimizu H, Kariminia A, Krailo M, **Chen Z**, McMaster R, Bergman A, Goldman F, Grupp SA, Wall DA, Gilman AL, Schultz KR.. Biomarkers in newly diagnosed pediatric extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. *Blood*. 2008; 111(6):3276-85.
 182. Malogolowkin MH, Katzenstein HM, Krailo M, **Chen Z**, Quinn JJ, Reynolds M., Ortega JA. Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. *Journal of Clinical Oncology*. 2008; 26(14):2379-83.
 183. Langevin AM, Bernstein M, Kuhn JG, Blaney SM, Ivy P, Sun J, **Chen Z**, Adamson PC. A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: A Children's Oncology Group study. *Pediatric Blood & Cancer*. 2008; 50(3):577-80.
 184. Korones DN, Fisher PG, Kretschmar C, Zhou T, **Chen Z**, Kepner J, Freeman C. Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: A Children's Oncology Group phase II study. *Pediatric Blood & Cancer*. 2008; 50(2):227-30.
 185. Bomgaars LR, Bernstein M, Krailo M, Kadota R, Das S, **Chen Z**, Adamson PC, and Blaney SM. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group study. *Journal of Clinical Oncology*. 2007; 25(29):4622-7.
 186. Schwartz CL, Gorlick R, Teot L, Krailo M, **Chen Z**, Goorin A, Grier HE, Bernstein ML, Meyers P, Children's Oncology Group. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. *Journal of Clinical Oncology*. 2007; 25(15):2057-62.
 187. Miser JS, Goldsby RE, **Chen Z**, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore SG, Rausen AR, Vietti TJ, Grier HE. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: Evaluation of increasing the dose intensity of chemotherapy-a report from the Children's Oncology Group. *Pediatric Blood & Cancer*. 2007; 49(7):894-900.
 188. Seibel NL, Krailo M, **Chen Z**, Healey J, Breitfeld PP, Drachtman R, Greffe B, Nachman J, Nadel H, Sato JK, Meyers PA, Reaman GH. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: Children's Cancer Group (CCG) 7943. *Cancer*. 2007;109(8):1646-1653.
 189. Bhatia S, Krailo MD, **Chen Z**, Burden L, Askin FB, Dickman PS, Grier HE, Link MP, Meyers PA, Perlman EJ, Rausen AR, Robison LL, Vietti TJ, Miser JS. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. *Blood*. 2007; 109(1):46-51.

190. She K, Gilman AL, Aslanian S, Shimizu H, Krailo M, **Chen Z**, Reid GS, Wall D, Goldman F, Schultz KR. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. *Biology Blood Marrow Transplant*. 2007; 13 (4):386-97.
191. Yock T, Krailo M, Fryer C, Donaldson S, Miser J, **Chen Z**, Bernstein M, Laurie F, Gebhardt M, Grier H, Tarbell N. Local control in pelvic Ewing's sarcoma: analysis from INT-0091. A report from the Children's Oncology Group. *Journal of Clinical Oncology*. 2006; 24(24):3838-43.
192. Malogolowkin MH, Katzenstein H, Krailo M, **Chen Z**, Bowman L, Reynolds M, Finegold M, Greffe B, Rowland J, Newman K, Womer R, Castleberry R. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. *Journal of Clinical Oncology*. 2006; 24(18):2879-84.
193. Zwerdling T, Krailo M, Monteleone P, Byrd R, Sato J, Dunaway R, Seibel N, **Chen Z**, Strain J, Reaman G. Phase II investigation of docetaxel (TAXOTERE®) in pediatric patients with relapsed solid tumors: a report from the Children's Oncology Group (COG). *Cancer*. 2006; 106(8):1821-1828.
194. Miralbell R, Fitzgerald TJ, Laurie F, Kessel S, Glicksman A, Friedman HS, Urie M, Kepner J, Zhou T, **Chen Z**, Barnes P, Kun L, Tarbell NJ. Radiotherapy in pediatric medulloblastoma: quality assessment of Pediatric Oncology Group Trial 9031. *International Journal of Radiation Oncology Biology and Physics*. 2006; 64(5):1325-30.
195. Greenberg ML, Fisher PG, Freeman C, Korones DN, Bernstein M, Friedman H, Blaney S, Hershon L, Zhou T, **Chen Z**, Kretschmar C, Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brain stem gliomas - A Pediatric Oncology Group Phase I study. *Pediatric Blood & Cancer*. 2005; 45(5):644-648.
196. Ozkaynak MF, Krailo M, **Chen Z**, Feusner J. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: A report from the Children's Oncology Group. *Pediatric Blood & Cancer* 2005; 45(3):274-80.
197. Angiolillo A, Whitlock J, **Chen Z**, Krailo M, Reaman G. A Phase II study of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): A Children's Oncology Group (COG) experience. *Pediatric Blood & Cancer* 2005; 46(2):193-197.
198. Shao QN, Shi DJ, Hao FY, Ma LN, **Chen Z**, Yu MM, Ru BG. Cloning and expression of metallothionein mutant alpha-KKS-alpha in *Anabaena* sp PCC 7120. *Marine Pollution Bulletin* 2002; 45 (1-12): 163-167.

199. **Chen Z**, Ren L, Shao Q, Shi D, Ru B. Expression of mammalian metallothionein-I gene in cyanobacteria to enhance heavy metal resistance. *Marine Pollution Bulletin* 1999; 39 (1-12): 155-158.
200. **Chen Z**, Li XF, Shi DJ, Ru BG. Studies on the purification, characterization and conformation in solution of metallothionein-like substance from *Synechocystis* 6803. *Acta Botanica Sinica* 1999; 41 (2): 150-155.
201. Guo X, **Chen Z**, Dan CT, Shi DJ, Ru BG. Purification and characterization of Metallothionein-like protein In *Synechococcus* sp. PCC 7942. *Chinese Biochemical Journal* 1997; 13 (6): 77-81.

Meeting Abstracts

1. **Chen Z**. Adaptive Approach for Estimating MTDs of Two Drugs by Fully Utilizing All Toxicity Data. The Southern Regional Council on Statistics (SRCOS) 55nd Summer Research Conference. 2019, Session V: New Advances in Clinical Trial.
2. Sahin IH, Chen W, Sonbol MB, Das S, **Chen Z**, Akce M, Alese OB, Shaib WL, Ahn DH, Ciombor KK, Borad MJ, Berlin J, Bekaii-Saab TS, Draper A, El-Rayes BF, Wu C. Analysis of age, tumor-sidedness, and mismatch repair (MMR) genes with response to immune checkpoint inhibitors (ICIs) in MMR-deficient (dMMR) colorectal cancer (CRC) patients (pts): A multi-institutional study. 2019 ASCO Annual Meeting. Abstract No: e15029.
3. Sahin IH, Chen W, **Chen Z**, Akce M, Alese OB, Shaib WL, El-Rayes BF, Wu C. Impact of genomic alterations (GAs) on outcomes and their distribution by age groups in metastatic colorectal cancer (mCRC) patients (pts). 2019 ASCO Gastrointestinal Cancers Symposium. Abstract ID#: 240471.
4. Mao J, Strouse CS, Goldman M, Chen W, **Chen Z**, Maurer MJ, Calzada O, Churnetski M, Flowers C, Cerhan JR, Link BK, Thompson CA, Cohen JB. Impact on survival of surveillance imaging after first remission in follicular lymphoma. 2019 ASCO Annual Meeting. Abstract No: 7536.
5. Patel U, Meisel JL, Barbee MS, Frinzi K, Sakach E, **Chen Z**. The clinical utility of strict laboratory monitoring of CDK 4/6 inhibitors in metastatic breast cancer patients. 2019 ASCO Annual Meeting. Abstract No: 1062.
6. Owonikoko TK, Higgins KA, **Chen Z**, Zhang C, Pillai RN, Steuer CE, Saba NF, Pakkala S, Shin DM, Zhang G, Wang S, Hossain MS, Beardslee T, Engelhart A, Revenig J, Khuri F, Curran WJ, Lonial S, Waller EK, Ramalingam SS. A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC). 2019 ASCO Annual Meeting. Abstract No: 8515.
7. Nazha B, **Chen Z**, Goyal S, Engelhart A, Carlisle JW, Beardslee T, Gill H, Odikadze L, Liu Y, Mishra MK, Behera M, Ramalingam SS, Owonikoko TK. Evaluating the role of race in

- outcome of advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitor (ICI): Our institutional experience. 2019 ASCO Annual Meeting. Abstract No: 9042.
8. Dhere V, Sudmeier L, Buchwald Z, Tian S, Jiang X, Zhang C, **Chen Z**, Eaton B, Shu HG, Crocker I, Curran W, Zhong J. Hypofractionated Radiation for Benign Meningiomas and Vestibular Schwannomas. 2019 ASTRO's 61st Annual Meeting. Poster #: 2218.
 9. Sudmeier LJ, AbugideirivM, Tian S, Goyal S, **Chen Z**, Eaton BR, Khan MK, Esiashvili N. Reduced Lung Dose is Associated with Decreased Incidence of Pulmonary Toxicity after Total Body Irradiation in Pediatric Patients. 2019 ASTRO's 61st Annual Meeting.
 10. Abiodun-Ojo OA, Jani AB, Akintayo AA, Alemozaffar M, Akin-Akintayo OO, Odewole O, Tade FI, Nieh PT, Master VA, Patel P, Shelton J, Kucuk O, **Chen Z**, Hershatter B, Fielder B, Halkar RK, Schuster DM. [¹⁸F]-fluciclovine positivity rate is not affected by androgen deprivation therapy (ADT) in recurrent prostate cancer post-prostatectomy. Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting.
 11. Abiodun-Ojo OA, Jani AB, Akintayo AA, Alemozaffar M, Akin-Akintayo OO, Tade FI, Master VA, Patel P, Shelton J, Kucuk O, **Chen Z**, Hershatter B, Schreibmann E, Fielder B, Halkar RK, Schuster DM. Findings on 18F-fluciclovine PET/CT with failure-free survival of salvage radiotherapy in post-prostatectomy patients with biochemical recurrence. RSNA 2019 annual meeting. Abstract No: 19014549.
 12. McCabe C, Barbee M, Watson M, Billmeyer A, Lee C, **Chen Z**, El-Rayes B, Haumschild R. Adherence Patterns to Oral Anticancer Medications at an Academic Medical Center for Patients Filling at an Internal Specialty Pharmacy versus an External Specialty Pharmacy. AMCP Annual Meeting 2019. Abstract ID: 594889.
 13. Zaidi MY, Ware MB, Krasinskas A, Farren MR, Li Y, **Chen Z**, Elnaggar O, Che Z, El-Rayes B, Maithel SK, Lesinski GB. Intratumoral Interleukin-6 and Myeloid Cell Subsets within the Cholangiocarcinoma Tumor Microenvironment. 2019 AHPBA meeting. Oral Abstracts #: 8.
 14. Hang TP, Spiritos Z, Gamboa A, **Chen Z**, Force S, Keilin S, Saba N, El-Rayes B, Cai Q, Willingham F. The Epidemiology of Esophageal Adenocarcinoma in the United States. ACG 2018 Annual Meeting. Abstract ID: P0265.
 15. Bernal-Mizrachi L, Cole CE, Heffner L, Nooka AK, Vij R, Kelkar N, Sridhar A, Cinar M, **Chen Z**, Chang Z, Lonial S and Kaufman KL. Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR). American Society of Hematology (ASH) 2018 Annual Meeting. Blood 2018 132:2011.
 16. **Chen Z**, Zhang Y, Kutner M, Kowalski J. Adaptive Bayesian Phase I Clinical Trial Design for Estimation of Maximum Tolerated Doses of Two Drugs While Fully Utilizing All Toxicity Information. 2018 ICSA China Conference.

17. Zhang Y, Kutner M, Kowalski J, **Chen Z**. Adaptive Bayesian Phase I Clinical Trial Design for Estimation of Maximum Tolerated Doses of Two Drugs While Fully Utilizing All Toxicity Information. ENAR 2018.
18. Goldman ML, Kim C, **Chen Z**, Calzada O, Churnetski M, Flowers C, Cohen JB. Surveillance Imaging during First-Remission in Follicular Lymphoma Does Not Impact Overall Survival. American Society of Hematology (ASH) 2018 Annual Meeting. Blood 2017 130:1501
19. Goldman ML, Kim C, **Chen Z**, Calzada O, Churnetski M, Flowers C, Cohen JB. High-Risk FLIPI Score at Diagnosis Is Associated with Early Relapse in the Rituximab Era for Patients with Follicular Lymphoma. American Society of Hematology (ASH) 2018 Annual Meeting. Blood 2017 130:5158
20. Goldman ML, Kim C, **Chen Z**, Calzada O, Churnetski M, Flowers C, Cohen JB. Results of Interim PET/CT Imaging During Front-line Induction in Follicular Lymphoma Do Not Predict Survival Outcomes. American Society of Hematology (ASH) 2018 Annual Meeting. Blood 2017 130:5156;
21. Robinson WE, Zhang Y, **Chen Z**, Calzada O, Churnetski M, Flowers CR, Cohen J. An Investigation of Potential Prognostic Factors in Late Relapse Diffuse Large B-cell Lymphoma Patients. American Society of Hematology (ASH) 2018 Annual Meeting. Blood 2017 130:5220.
22. Press RH, Morgan TM, Cutrell PK, Zhang C, **Chen Z**, Rahnema S, Sanda M, Pattaras J, Patel P, Jani AB, Rossi PJ. Patient Reported Quality of Life Outcomes after HDR Brachytherapy between Small (<60cc) and Large (≥60cc) Prostate Glands. American Brachytherapy Society (ABS) 2018 Annual Meeting.
23. Wade J, Little J, Zhang C, **Chen Z**, Meisel J, Hanley KZ. Pathologic characteristics of node positive invasive breast carcinomas associated with extranodal extension. USCAP 2018 Annual Meeting. Abstract No: 137.
24. Abiodun-Ojo OA, Jani AB, Akintayo AA, Alemozaffar M, Akin-Akintayo OO, Odewole O, Tade FI, Nieh PT, Master VA, Patel P, Shelton J, Kucuk O, **Chen Z**, Hershatter B, Fielder B, Halkar RK, Goodman MM, Schuster DM. Change in salvage radiotherapy management based on fluciclovine (¹⁸F) PET/CT guidance in post-prostatectomy recurrent prostate cancer. RSNA 2018 annual meeting. Abstract No: 18010759.
25. Chen GZ, Wang D, Griffith C, Nannapaneni S, Steuer C, Patel M, El-Deiry M, Wang X, Zhang Y, **Chen Z**, Alvarado D, Shin DM, Saba NF. Effective reduction of PD-L1 expression by simultaneous blockage of EGFR and HER3 (ErbB3) in head and neck cancer. 2018 AACR Annual Meeting Abstract No: 7266.

26. Saba N, Force S, Staley C, Fernandez F, Willingham F, Pickens A, Cardona K, **Chen Z**, Goff L, Cardin D, Lambright E, Nesbitt J, Higgins K, Harvey DR, Owonikoko T, Ramalingam S, Shin D, Beitler J, El-rayes B, Salaria S, El-Rifai W, Landry J, Chakravarthy B. Pilot Study of Potential Activation of c-MYC by Aurora Kinase A in Everolimus-Resistant Localized Esophageal Cancer Treated with XELOX followed by Carboplatin/Radiation. ASTRO 2018 Annual Meeting. Abstract No: SU_7_2061.
27. Abugideiri M, Press RH, Zhang C, Thomas M, Tian S, Jhaveri J, R. J. Cassidy III RJ, Zaenger D, Morgan T, Madden N, Parks J, Buchwald ZS, Morrison D, **Chen Z**, Robertson Y, Phillips R, Landry JC, and Godette KD. ASTRO 2018 Annual Meeting. Abstract No: .
28. Shaib WL, Sayegh L, Alese OB, Maithel S, Cardona K, Sarmiento J, Belalcazar A, Ip A, Qu Y, Akce M, Zhang C, Wu C, **Chen Z**, El-Rayes BF. Resection of pancreatic cancer following induction chemotherapy. 2018 Gastrointestinal Cancers Symposium. Abstract No: 203305.
29. Morgan T, Press RH, Cutrell P, Zhang C, **Chen Z**, Rahnema S, Sanda MG, Pattaras J, Patel PR, Jani AB, Rossi PJ. Hypofractionated external beam radiation therapy in combination with HDR boost for localized prostate cancer: Quality of life outcomes. 2018 Genitourinary Cancers Symposium. Abstract No: 206539.
30. Patel N, Wu C, Draper A, LaFollette JA, Brutcher E, El-Rayes BF, Alese OB, Shaib W, Akce M, **Chen Z**, Kim C. Retrospective study of the safety of administering pegfilgrastim on the same day of 5- Fluorouracil pump disconnect. 2018 ASCO Annual Meeting. Abstract No: 214181.
31. Carlisle JW, Nho NT, Kim C, **Chen Z**, Li S, Hill C, Ramalingam SS, Sica G, Owonikoko TK. Impact of TP53 mutations on efficacy of PD-1 targeted immunotherapy in non-small cell lung cancer (NSCLC). 2018 ASCO Annual Meeting. Abstract No: 229755.
32. Gogineni K, Sauter C, Zhang C, **Chen Z**, Smith D. BRCA Testing Patterns at a Safety Net Hospital and an Academic Medical Center. San Antonio Breast Cancer Symposium (SABCS) 2017.
33. Gogineni K, Sauter C, Zhang C, **Chen Z**, Smith D. BRCA Testing Patterns at a Safety Net Hospital and an Academic Medical Center. AACR annual meeting 2017.
34. Rahman MA, Wang P, Wang D, Hurwitz SJ, **Chen Z**, Chen ZG, Ke Y, Shin DM. Efficient delivery of Bcl2 siRNA by DNA nanoparticles to inhibit cellular growth and cancer progression. AACR annual meeting 2017. Abstract No: 187.
35. Wang D, Magliocca KR, Nannapaneni S, Steuer C, Patel MR, El-Deiry MW, Wang X, **Chen Z**, Shin DM, Saba NF, Chen ZG. Combinatory approaches targeting EGFR, HER2 and c-MET in recurrent SCCHN. AACR annual meeting 2017. Abstract No: 4110.

36. Rossi PJ, Jeans E, Cutrell PK, Zhang C, **Chen Z**, Rahnema S, Sanda M, Pattaras J. Patient Reported Outcomes in Prostate Cancer Treated with a CT based High and Low Dose Rate Brachytherapy. ABS 2017.
37. Brucher EA, **Chen Z**, Pan A, Barrett T. Prevalence of Zinc Deficiency in Patients with Upper GI Cancer on Chemotherapy. ONS (oncology Nursing Society) Congress meeting in May 4-, 2017. That abstract will also be publish as, “The Relationship between Zinc and QOL in Patients with Upper GI Cancer on Chemotherapy” in the online Congress issue of the Oncology Nursing Forum.
38. Pokala SK, **Chen Z**, Mekaroonkamol P, Keilin S, Cai Q, Willingham FF. Incidence and Survival in Gastric Adenocarcinoma and Early Gastric Adenocarcinoma in the United States. DDW 2017 Abstract # 2682311.
39. Pokala SK, **Chen Z**, Mekaroonkamol P, Gamboa A, Keilin S, Cai Q, Willingham FF. Incidence, Survival, and Predictors of Lymph Node Metastasis in Early Stage Gastric Cardia Adenocarcinomas in the United States. DDW 2017 Abstract # 2682201.
40. Pokala SK, **Chen Z**, Mekaroonkamol P, Gamboa A, Keilin S, Cai Q, Willingham FF. Predictors Of Lymph Node Involvement In Early Stage Gastric Adenocarcinoma In The United States. DDW 2017 Abstract # 2682070.
41. Pokala SK, **Chen Z**, Mekaroonkamol P, Gamboa A, Keilin S, Cai Q, Willingham FF. Incidence, Survival, and Predictors of Lymph Node Metastasis in Early Stage Gastric Signet Ring Cell Carcinomas in the United States. DDW 2017 Abstract # 2682392.
42. Saba NF, Force SD, Staley CA, Fernandez FG, Willingham FF, Allan P, Cardona K, **Chen Z**, Cardin DB, Lambright E, Nesbitt J, Higgins KA, Harvey DR, Owonikoko TK, Ramalingam S, Shin DM, Beitler JJ, El-Rayes BF, Landry JC, Chakravarthy AB. Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer (EC). 2017 ASCO Annual Meeting. Abstract No: e15607.
43. Chen ZG, Nannapaneni S, Griffith CC, Wang D, Zhang C, Magliocca KR, Wang X, **Chen Z**, Patel M, Steuer CE, Shin DM, Saba NF. FGFR3 correlation with mutant p53 and its prognostic value in oropharyngeal squamous cell carcinoma (OPSCC). 2017 ASCO Annual Meeting. Abstract No: 6057.
44. Pant S, Owonikoko TK, Catherine S, Diefenbach M, Kim S, **Chen Z**, Towle EL, Pierce L, Mileham KF. Collection and utilization of oncology big data. 2017 ASCO Annual Meeting. Abstract No: e18134.
45. **Chen Z**, Yuan Y, Li Z, Kutner M, Jeanne Kowalski J. Dose Escalation with Over-dose and Under-dose Control in Phase I/II Clinical Trials. The 10th ICSA International Conference. 2016 December 19-22.

46. **Chen Z**, Li Z, Yuan Y, Kutner M, Owonikoko TK, Curran W, Kowalski J. Adaptive estimation of personalized maximum tolerated doses in cancer phase I clinical trials according to all toxicities and individual characteristics. JSM 2016 August 2. Abstract No: 319671.
47. **Chen Z**. Estimation of personalized maximum tolerated dose (pMTD) according to patient's biomarkers in cancer Phase I clinical trial. East Lake International Forum for Outstanding Overseas Young Scholars at Huazhong University of Science & Technology (HUST) 2015.
48. Cox KL, Nandwana S, Olaiya B, Mittal PK, Ibraheem O, **Chen Z**, Zhang C, Smith A. MRI Liver Surface Nodularity Score as a New Noninvasive Biomarker for Chronic Viral Hepatitis. Radiology Society of North America (RSNA) 102nd Annual Meeting 2016. Abstract No: 16017485.
49. Gilbert-Ross M, Konen J, Koo J, Shupe J, Sica GL, **Chen Z**, Robinson BS, Behera M, Rossi MR, Smith GH, Hill CE, Ramalingam SM, Fu H, Khuri FR, Zhou W, Marcus A. Developing a personalized anti-metastatic therapy to treat KRAS, LKB1-mutant lung adenocarcinoma. AACR annual meeting 2016. Abstract No: LB-348.
50. Wang D, Qian G, Zhang H, Magliocca KR, Nannapaneni S, **Chen Z**, Patel MR, El-Deiry MW, Wadsworth TJ, Shin DM, Khuri FR, Saba NF, Chen ZG. HER3 targeting sensitizes HNSCC to cetuximab - evidence from cell line and patient derived xenograft (PDX) models. AACR annual meeting 2016. Abstract No: 1866.
51. Copur AS, Everhart DE, Zhang C, **Chen Z**, Shekhani H, Matheivosan S, Loveless J, Watson E, Kadri I, Wallace L, Simon E, Fulambarker A. Effect of Personality Trait for PAP Therapy Adherence in Obstructive Sleep Apnea Patients. American College of Chest Physician (ACCP) meeting 2016.
52. **Chen Z**, Yuan Y, Li Z, Kutner M, Owonikoko TK, Curran W, Khuri F, Kowalski J. Dose Escalation with Over Dose and Under Dose Control for Phase I/II Clinical Trials. JSM 2015 August 2. Abstract No: 315069.
53. Pooja Chandra, Olufunke Akinbobuyi, Albert Liao, Jyoti Arora, Zhengjia Chen, Mary J Lechowicz, Amelia A. Langston, Jeanne Kowalsky, Jonathon B. Cohen, Christopher R Flowers and Leon Bernal-Mizrachi. Suvmax in 18-Fluorodeoxyglucose PET/CT Potentially Predict the Estimation of a Positive Biopsy in Cases of Lymphoma. American Society of Hematology (ASH) 2016 Annual Meeting. Blood 2015 126:5043.
54. Owonikoko TK, Kowalski J, Kim S, Dwivedi B, **Chen Z**, Behera M, Mayfield W, Hermann RC, Chen L, Khuri FR, Ramalingam SS, Sica G. PD-L1, PD-1, and CTLA-4 as prognostic biomarkers in resected non-small cell lung cancer. 2015 ASCO Annual Meeting. Abstract No: 7551.

55. Alese OB, Kim S, **Chen Z**, Owonikoko TK, El-Rayes BF. Pattern of liver-directed therapies and outcomes in cancer patients hospitalized in the United States. 2015 ASCO Annual Meeting. Abstract No: e15112.
56. Alese OB, Kim S, **Chen Z**, Shaib WL, Owonikoko TK, El-Rayes BF. Management and outcomes of hospitalized patients with primary neuroendocrine tumor (NET) and non-NET appendiceal cancers in the United States. 2015 ASCO Annual Meeting. Abstract No: e17722.
57. Shaib WL, Qu J, Zhang C, Ip A, **Chen Z**, El-Rayes BF, Alese O. Borderline resectable (BRPC) and locally advanced unresectable (LAPC) pancreas cancer treatment: A single Institution experience. 2015 ASCO Annual Meeting. Abstract No: e15260.
58. Mohamed A, Schrapp K, Owonikoko TK, Steuer CE, **Chen Z**, Pakkala S, Pillai RN, Wadsworth JT, Higgins KA, Ramalingam S, Beitler J, Shin DM, Khuri FR, Behera M, Saba NF. Concurrent chemoradiation using weekly versus tri-weekly cisplatin in locally advanced squamous cell carcinoma of the head and neck (SCCHN): A comparative analysis. 2015 ASCO Annual Meeting. Abstract No: e15260.
59. Owonikoko TK, Nelson M, Park SY, Kim S, Steuer CE, Behera M, **Chen Z**, Han E, Kumar M, Ernani V, Saba NF, Khuri FR, Ramalingam SS, Rossi MR. Aneuploidy of anaplastic lymphoma kinase (ALK) gene and association with non squamous lung cancer patient characteristics and outcomes. 2015 ASCO Annual Meeting. Abstract No: 7549.
60. El-Rayes BF, Shaib WL, Williams R, **Chen Z**, Ganji NP, Brucher E, Kim HS. Phase Ib study of pasireotide (P), everolimus (E), and selective internal radioembolization therapy (SIRT) for unresectable neuroendocrine hepatic metastases. 2015 ASCO Annual Meeting. Abstract No: 4092.
61. Geiger C, **Chen Z**, Zhang C, Behera M, Steuer CE, Pillai RN, Ramalingam SS. Investigating the correlation between disease burden and symptoms in patients with advanced stage lung cancer. 2015 ASCO Annual Meeting. Abstract No: e19057.
62. Patel K, Asher A, Burri S, Fraser R, Kandula S, Press R, **Chen Z**, Zhang C, Hadjipanayis C, Olson J, Oyesiku N, Curran W, Shu HK, Crocker I, Prabhu R. Comparing Preoperative Stereotactic Radiosurgery (SRS) to Postoperative SRS for Resectable Brain Metastases. 2015 ASTRO 57th Annual Meeting. Presentation #: 85.
63. Prabhu RS, Patel KR, Burri SH, Zhang C, **Chen Z**, Crocker IR, Fraser RW, Wait SD, Kandula S, Hadjipanayis C, Curran W, Shu HK, MD, Asher A. Patterns of Recurrence and Toxicity for Pre-operative versus Post-operative Stereotactic Radiosurgery (SRS) for Resected Brain Metastases: A Multi-Institutional Analysis. The College of Neurosurgeons meeting 2015.
64. Jani AB, Schreibmann E, Rossi P, Shelton J, Godette K, Nieh P, Master V, Kucuk O, Goodman M, Halkar R, Cooper S, **Chen Z**, Schuster D. Impact of anti-3-[18F]FACBC

Positron Emission Tomography on Target Volume Definition after Prostatectomy: Initial Findings from a Randomized Trial. 2015 ASTRO 57th Annual Meeting.

65. Wang X, Beitler J, Huang W, Qian G, Magliocca K, Zhang J, Nannapaneni S, Kim S, **Chen Z**, Nabil S, Chen ZG, Arbiser JL, Shin DM. Honokiol radiosensitizes squamous cells carcinoma of head and neck by down-regulation of surviving. AACR annual meeting 2015. Abstract No: 20.
66. Qian G, Wang D, Magliocca KR, Duggal P, Nannapaneni S, Kim S, **Chen Z**, Shin DM, Saba NF, Chen ZG. Human papillomavirus 16 oncoprotein E6 upregulates c-Met partially through p53 in squamous cell carcinoma of the head and neck. AACR annual meeting 2015. Abstract No: 813.
67. Peng X, Macke M, Shin H, Nannapaneni S, **Chen N**, Kim S, Chen ZG, El-Sayed M, Shin D. The nuclear-targeted gold nanoparticles inhibit the tumor growth in mouse model as potential anticancer agents. AACR annual meeting 2015. Abstract No: 2451.
68. Owonikoko TK, Harvey D, Lewis C, **Chen Z**, Kauh J, Renfro M, Deovic R, Sica G, Carthon B, Harris WB, El-Rayes BF, Ramalingam SS, Khuri FR. A phase I pharmacokinetic and pharmacodynamic evaluation of the combination of everolimus and buparlisib for concurrent mTOR and PI3K pathway blockade in patients with advanced solid tumors. AACR annual meeting 2015. Abstract No: CT303.
69. **Chen Z**, Zhao Y. Adaptive and Sequential Methods for Clinical Trials. ICASA-KISS 2014 Applied Statistics Symposium. 2014 June 16-18.
70. **Chen Z**. Estimation of personalized maximum tolerated dose (pMTD) according to patient's biomarkers in cancer Phase I clinical trial. BIT's 4th Annual World Congress of MolMed-2014. November 13-16.
71. Li Z, Kutner M, Yuan Y, **Chen Z**. Dose Escalation with Over-dose and Under-dose Controls for Phase I/II Clinical Trials. ENAR 2014.
72. Chandra Pooja, Ajay K. Nooka, Monica S. Chatwal, Sungjin Kim, Zhengjia Chen, Jeanne Kowalski, Jonathan L. Kaufman, Sagar Lonial and Leon Bernal-Mizrachi. Outcomes for Myeloma in the Era of Lenalidomide Maintenance Are Not Different Among Ethnic Groups Following Autologous Transplant. American Society of Hematology (ASH) 2014 Annual Meeting. Blood 2014 124:3973;
73. Leon Bernal-Mizrachi, Ajay K Nooka, Chandra Pooja, Monica S Chatwal, Sungjin Kim, Zhengjia Chen, Jeanne Kowalski, Jonathan L. Kaufman and Sagar Lonial. Racial Disparity in Patients with Multiple Myeloma Are Blunted in the Era Novel Therapies. American Society of Hematology (ASH) 2014 Annual Meeting. Blood 2014 124:2525.
74. Kim S, Owonikoko TK, Li Z, Votaw J, Kutner M, Khuri F, Kowalski J, **Chen Z**. Application of Normalized Equivalent Toxicity Score (NETS) System to Fully Utilize All Toxicities in

Common Phase I Clinical Trial Designs. The Society for Clinical Trials 35th Annual Meeting. 2014 May 18-21.

75. Wang X, Qian X, Beitler JJ, Zhang J, Kang H, Chen ZG, Magliocca KR, Wang X, **Chen Z**, Nie S, Shin DM. Evaluation prognostic significance of circulating tumor cells (CTCs) using multiplexed gold nanoparticles in patients with head and neck cancer. AACR annual meeting 2014. Abstract No: 4829.
76. Wang D, Qin X, Qian G, Halig L, Fei B, **Chen Z**, Chen ZG, Saba NF, Shin DM, Xu H, Wang AY. EGFR targeted iron-oxide nanoparticles for photodynamic therapy in head and neck cancer. AACR annual meeting 2014. Abstract No: 3323.
77. Qian G, Xu H, Hu Z, Kim S, Wang D, Zhang H, **Chen Z**, Muller S, Saba N, Shin DM, Wang AY, Chen ZG Enhancing specificity in predication of human papillomavirus associated oropharyngeal squamous cell carcinoma by combining biomarkers p16 and β -catenin. AACR annual meeting 2014. Abstract No: 1852.
78. Owonikoko TK, Zhang G, Sica G, **Chen Z**, Switchenko JM, Kim S, Gal A, Ramalingam S, Deng X, Rossi M, Kowalski J, Khuri F. Evaluating markers of cisplatin sensitivity and survival in small cell lung cancer. AACR annual meeting 2014. Abstract No: 922.
79. Colbert LE, Fisher S, Balci S, **Chen Z**, Kim S, Adsay V, Maithel S, El-Rayes BF, Landry J, Curran W. Nuclear Hypoxia-Inducible Factor 1 Alpha is a predictor of distant failure in patients with resected pancreatic adenocarcinoma. 2014 ASTRO 56th Annual Meeting. Abstract #: 2014-A-1454-ASTRO.
80. Kirkland R, Khan M, Kim S, **Chen Z**, Cash T, Esiashvili N. Stratifying Pulmonary Tumor Burden in Patients with Stage IV Wilms Tumor (WT): Implications for Treatment and Disease Outcome. 2014 ASTRO 56th Annual Meeting. Abstract #: 2014-A-1635-ASTRO.
81. Steuer C, Behera M, Kim S, Patel N, **Chen Z**, Pillai R, Saba N, Shin DM, Owonikoko TK, Khuri F, Ramalingam S. Predictors and outcomes of venous thromboembolism (VTE) in hospitalized lung cancer patients: A nationwide inpatient sample (NIS) database analysis. 2014 ASCO Annual Meeting. Abstract No: 130499.
82. Alese OB, Kim S, **Chen Z**, Owonikoko TK, El-Rayes B. Mortality from malignant bowel obstruction in hospitalized US cancer patients. 2014 ASCO Annual Meeting. Abstract No: 130443.
83. Steuer C, Behera M, Kim S, **Chen Z**, Pillai R, Owonikoko TK, Khuri F, Ramalingam S. Clinical characteristics and outcomes of atypical carcinoid (AC) tumor of the lung: A surveillance, epidemiology, and end results database analysis. 2014 ASCO Annual Meeting. Abstract No: 130365.
84. Zhang H, Kim S, **Chen Z**, Nannapaneni S, Sica G, Carey T, William WN, Nguyen ML, Riddell J, Pai S, Walline HM, Lee JJ, Wolf GT, Grandis JR, Ferris RL, Chen ZG, Shin DM.

- Expression of tumor biomarkers in HIV-infected patients with head and neck cancer. 2014 ASCO Annual Meeting. Abstract No: 134116.
85. Behera M, Steuer C, Kim S, Pillai RN, **Chen Z**, Owonikoko TK, Belani CP, Khuri F, Ramalingam S. Management approaches and outcomes of lung cancer patients hospitalized for malignant pleural effusions. 2014 ASCO Annual Meeting. Abstract No: 133907.
86. Behera M, Ragin C, Kim S, **Chen Z**, Steuer C, Saba NF, Pillai RN, Belani CP, Ramalingam S, Khuri FR, Owonikoko TK. Trends in small cell lung cancer (SCLC) survival: Predictors and impact of systemic therapy. 2014 ASCO Annual Meeting. Abstract No: 132586.
87. Hanasoge S, Wang X, **Chen Z**, Mister D, Miller A, Torres M. The influence of radiotherapy on sleep disturbances in breast cancer patients. 2014 ASCO Annual Meeting. Abstract No: 129758.
88. Saba NF, Qian G, Ning J, **Chen Z**, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG. Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC). 2014 ASCO Annual Meeting. Abstract No: 131778.
89. **Chen Z**, Cui Y, Li Z, Yuan Y, Owonikoko TK, Votaw J, Kutner M, Khuri F, Kowalski J. Bayesian Adaptive Approach: Dose Escalation with Over Dose and Under Dose Control for Phase I/II Clinical Trials. The 9th ICSA International Conference. 2013 December 19-24.
90. **Chen Z**, Cui Y, Owonikoko TK, Wang Z, Shin DM, Khuri F, Kowalski J. Continuous Tumor Size Change Percentage and Progression Free Survival as Endpoint of the First and Second Stage Respectively in a Novel Double Screening Phase II Design. The Society for Clinical Trials 34th Annual Meeting. 2013 May 19-22.
91. Cui Y, Owonikoko TK, Wang Z, Khuri F, Kowalski J, **Chen Z**. Escalation with Overdose Control using All Toxicities and Time to Toxicity Data for Cancer Phase I Clinical Trials. The Society for Clinical Trials 34th Annual Meeting. 2013 May 19-22.
92. Wang Z, Owonikoko TK, Kowalski J, Khuri F, **Chen Z**. Interactive Statistical Software for Estimating the Operating Characteristics of Cancer Phase I Clinical Trial Designed with Standard 3+3 Algorithm. The Society for Clinical Trials 34th Annual Meeting. 2013 May 19-22.
93. R. Donald Harvey, Meagan S. Barbee, Ajay K. Nooka, Sungjin Kim, **Zhengjia Chen**, Leonard T. Heffner, Jonathan L. Kaufman and Sagar Lonial. Predictors Of Survival Outcomes In Phase I Relapsed Or Refractory Multiple Myeloma Patients. American Society of Hematology (ASH) 2013 Annual Meeting. Blood 2013 122:1958.
94. Joshi JP, **Chen Z**, Nahta R. Growth differentiation factor 15 causes increased invasiveness and EMT in HER2-overexpressing breast cancer via activation of p38 MAPK. AACR annual meeting 2013. Abstract No: 889/17.

95. Owonikoko TK, Miller D, Force S, Sica G, Kono S, Behera M, Mendel J, **Chen Z**, Pickens A, Fu R, Auffermann W, Rogerio J, Torres W, Fu H, Hohneker J, Sun SY, Gal A, Ramalingam S, Khuri F. Window of opportunity preoperative interrogation of mTOR pathway in patients with resectable non-small cell lung cancer (NSCLC). AACR annual meeting 2013. Abstract No: LB-194.
96. Saba N, Kono S, Mendel J, Hurwitz S, Owonikoko TK, Lewis C, Harvey D, Rogerio JW, **Chen Z**, Wadsworth T, El-Deiry M, Chen AY, Higgins K, Ramalingam S, Beitler J, Shin DM, Khuri FR. Carboplatin (C), cetuximab (Cet), and everolimus (E) in recurrent or metastatic squamous cell carcinoma of the head and neck (RMSCCHN). Results of a phase Ib study. 2013 ASCO Annual Meeting. Abstract No: 6083.
97. Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, Jiang K, **Chen Z**, Wang X, Curran W, Khan M. Patterns of failure in advanced-stage diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP chemotherapy and the emerging role of consolidative radiotherapy. 2013 ASCO Annual Meeting. Abstract No: 8546
98. Behera M, Pillai RN, Owonikoko TK, Kim S, **Chen Z**, Saba N, Belani C, Khuri FR, Ramalingam S. Bevacizumab in combination with taxane versus non-taxane-containing regimens for advanced/metastatic nonsquamous non-small-cell lung cancer (NSCLC): A systematic review. 2013 ASCO Annual Meeting. Abstract No: e19094
99. Eaton BR, Marcus DM, Kim S, **Chen Z**, Ramalingam S, Curran W, Higgins K. Prophylactic cranial irradiation in patients ≥ 70 years old with limited stage small cell lung cancer: A Surveillance, Epidemiology, and End Results analysis. 2013 ASCO Annual Meeting. Abstract No: 7589
100. Pillai RN, Ragin C, Sica G, Behera M, **Chen Z**, Kim S, Mayfield W, Hermann RC, Saba N, Gal A, Khuri FR, Ramalingam S, Owonikoko TK. Human papillomavirus (HPV)-associated early stage non-small cell lung cancer (NSCLC). 2013 ASCO Annual Meeting Abstracts. Abstract No: 7560
101. Kang H, Kim S, **Chen Z**, El-Rayes BF, Brandes J, Saba N, Khuri FR, Ramalingam S, Owonikoko TK. A retrospective cohort study of inpatient chemotherapy utilization in hospitalized advanced lung cancer patients in the United States. 2013 ASCO Annual Meeting Abstracts. Abstract No: 6611
102. Alese OB, El-Rayes BF, Sica G, Zhang G, Rossi MR, Adsay V, Alexis D, La Rosa F, Varella-Garcia M, **Chen Z**, Kauh JS, Ramalingam S, Khuri FR, Owonikoko TK. Multiplatform assessment of anaplastic lymphoma kinase (ALK) gene rearrangement in signet ring cell carcinoma of the gastrointestinal tract. 2013 ASCO Annual Meeting Abstracts. Abstract No: e14612

103. Shaib WL, Sharma R, Kim S, **Chen Z**, Kauh J, Kooby D, Maithel S, Landry JC, El-Rayes BF. Survival outcome of ampullary and duodenal adenocarcinomas. 2013 ASCO Annual Meeting Abstracts. Abstract No: e14579.
104. **Chen Z**, Wang Z, Owonikoko TK, Kowalski J, Khuri FR. Interactive Software “Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS)” for Cancer Phase I Clinical Trials. The Society for Clinical Trials 33th Annual Meeting. 2012 May 20-23. Abstract No: B08.
105. Wang Z, Owonikoko TK, Kowalski J, Khuri FR, **Chen Z**. A Novel Statistical Software EWOC-NETS[®]™ for Extending Dose Escalation with Overdose Control (EWOC) to Fully Utilize All Toxicities in Cancer Phase I Clinical Trial. The Society for Clinical Trials 33th Annual Meeting. 2012 May 20-23. Abstract No: B11.
106. **Chen Z**, Kim S, Owonikoko TK, Wang Z, Ramalingam S, Shin D, Khuri F, Kowalski J. Changes in tumor size as a continuous variable in Phase II trials rather than WHO/RECIST response to improve success rate of confirmatory Phase III trials. JSM 2012 July 28 – August 2. Abstract No: 305415.
107. Cui Y, Owonikoko TK, Wang Z, Kim S, Shin D, Khuri F, Kowalski J, **Chen Z**. A Novel Phase II Design to Minimize Trial Duration and Improve the Success Rate of Follow-up Phase III Trial. JSM 2012 July 28 – August 2. Abstract No: 305019.
108. Webber G, Rivas M, **Chen Z**, Nichols L, El-Rayes B, Kim HS; Quality of Life Assessment after Doxorubicin Drug-Eluting Beads Transarterial Chemoembolization (DEB-TACE) in Patients with Hepatocellular Carcinoma (HCC), The 37th Annual Scientific Meeting of the Society of Interventional Radiology, 2012 March, San Francisco, CA . Abstract No: 1253668.
109. Prajapati H, **Chen Z**, Spivey JR, Hanish SI, El-Rayes B, Kauh J, Kim HS; Correlation of Survival and Tumor Response with WHO, RECIST, EASL and mRECIST Criteria after Doxorubicin Drug Eluting Beads Transarterial Chemoembolization (DEB TACE) in Unresectable Hepatocellular Carcinoma (HCC), The 37th Annual Scientific Meeting of the Society of Interventional Radiology, 2012 March, San Francisco, CA. Abstract No: 1252933.
110. Park W, Vallabhaneni GD, Martin LK, Adsay V, Staley CA, Maithel SK, Wang Z, **Chen Z**, El-Rayes BF, Bekaii-Saab TS. Clinicopathologic feature and outcome of appendiceal goblet cell carcinoid and neuroendocrine tumor. *American Society of Clinical Oncology Annual Meeting 2012*. June 1-5. Abstract No: 100915.
111. Bekaii-Saab T, Martin LK, Vallabhaneni GD, Park W, Staley CA, Maithel SK, Wang Z, **Chen Z**, El-Rayes BF. A comparative analysis of locoregional therapy (hyperthermic intraperitoneal chemotherapy [HIPEC]) and systemic chemotherapy (CT) following cytoreductive surgery in patients (pts) with disseminated mucinous appendiceal cancers (MACA). *American Society of Clinical Oncology Annual Meeting 2012*. June 1-5. Abstract No: 100897.

112. Behera M, Beitler JJ, Bhimani C, Higgins K, **Chen Z**, Kim S, Deng X, Curran W, Khuri FR, Ramalingam S, Owonikoko TK. A systematic analysis of high-dose radiation in the treatment of surgically unresectable, locally advanced non-small cell lung cancer. *American Society of Clinical Oncology Annual Meeting 2012*. June 1-5. Abstract No: 100242.
113. Chowdry RP, Sica G, **Chen Z**, Goodman A, Kim S, Deng X, Curran W, Gal A, Khuri FR, Ramalingam S, Owonikoko TK. Expression pattern and biologic relevance of Bcl-2 and Mcl-1 in pulmonary neuroendocrine tumors. *American Society of Clinical Oncology Annual Meeting 2012*. June 1-5. Abstract No: 98916.
114. Owonikoko TK, Kono SA, Saba NF, **Chen Z**, Arabnia A, Chen AY, Grist W, Brandt SF, Jacob S, Srivatsa S, Sharma J, Weber CJ, Kane MA, Lorch JH, Grzegorzewski K, Rogerio JW, Ramalingam SS, Shin DM, Khuri FR. A multicenter phase II study of everolimus and pasireotide (SOM230) LAR in advanced metastatic thyroid cancer. *American Society of Clinical Oncology Annual Meeting 2012*. June 1-5. Abstract No: 98273.
115. Owonikoko TK, Harvey DR, Kauh JS, Lewis CM, Hossain MS, Akintayo AO, A. Merriewether R, **Chen Z**, Hawk NN, Saba NF, Harris W, Shin DM, El-Rayes BF, Huang C, Lonial S, Lawson DH, Khuri FR, Waller EK, Ramalingam S. A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies. *American Society of Clinical Oncology Annual Meeting 2012*. June 1-5. Abstract No: 98629.
116. Saba N, Magliocca KR, Kim S, Muller S, **Chen Z**, Eggers C, Phelan V, Kono S, Owonikoko TK, Ramalingam S, Grist W, Chen AY, Beitler JJ, Shin DM, Marcus A, Khuri FR. Acetylated tubulin and risk of nodal metastases in squamous cell carcinoma of the head and neck (SCCHN). . *American Society of Clinical Oncology Annual Meeting 2012*. June 1-5. Abstract No: 96948.
117. Mahaseth H, Kauh JS, Brutcher E, Hawk N, Kim S, **Chen Z**, El-Rayes B. Safety and efficacy of modified FOLFIRINOX in pancreatic cancer: A retrospective experience. *American Society of Clinical Oncology Annual Meeting 2012*. June 1-5. Abstract No: 93988.
118. Prajapati H, Spivey JR, Hanish SI, **Chen Z**, El-Rayes BF, Kauh JS, Kim HS. Magnetic Resonance Imaging Predicts Survival After Doxorubicin Drug Eluting Beads Chemoembolization In Unresectable Hepatocellular Carcinoma. The 62nd Annual Meeting of the American Association for the Study of Liver Diseases November 4-8, 2011 San Francisco, CA Abstract ID: 1135.
119. **Chen Z**, Tighiouart M, Liu Y, Wang Z, Owonikoko TK, Kowalski J. Escalation With Overdose Control Using Normalized Equivalent Toxicity Score And Patients' Characteristics To Define Personalized Maximum Tolerated Dose In Phase I Clinical Trial. JSM 2011 July 29 – August 5. Abstract No: 300885

120. Khuri FR, Owonikoko TK, Subramanian J, Sica G, Behera M, Saba NF, **Chen Z**, Tighiouart M, Shin DM, Sun S, Fu R, Gal A, Govindan R, Ramalingam SS. Everolimus, an mTOR inhibitor, in combination with docetaxel for second- or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study. *American Society of Clinical Oncology Annual Meeting 2011*. June 3-7. Abstract No: e13601
121. Behera M, Owonikoko TK, **Chen Z**, Kono SA, Khuri FR, Belani CP, Ramalingam SS; Single-agent maintenance therapy for advanced-stage non-small cell lung cancer: A meta-analysis. *American Society of Clinical Oncology Annual Meeting 2011*. June 3-7. Abstract No: 7553
122. Sampath Ramachandiran, Xiangxue Guo, Laurent Garderet, Souhila Ikhlef, Jean El-cheikh, Michael R Weil, Andrew N Young, Mahir Bagirov, Sagar Lonial, **Zhengjia Chen**, Jeanne Kowalsky, Yuhong Du, Hanna J. Khoury, Susan Sunay, Jonathan L. Kaufman, Lawrence H. Boise, Michael Rossi and Leon Bernal-Mizrachi. Truncation of NF-KB2 Is Associated with Poor Response to Bortezomib Treatment in Multiple Myeloma. American Society of Hematology (ASH) 2011 Annual Meeting. Blood 2011 118:2891.
123. Owonikoko TK, Behera M, Tran HN, **Chen Z**, Chowdry RP, Saba NF, Ramalingam SS, Khuri FR; Systematic comparative analysis of efficacy of EGFR tyrosine kinase inhibitors (TKIs) in the frontline versus salvage therapy of NSCLC. *American Society of Clinical Oncology Annual Meeting 2011*. June 3-7. Abstract No: 7602
124. Hossain S, Bhimani C, **Chen Z**, Ramalingam SS, Shin DM, Cohen C, Khuri FR, Waller E, Owonikoko TK. Comparison of native and adaptive immunity profiles of healthy volunteers and patients with well-differentiated thyroid cancer. *American Society of Clinical Oncology Annual Meeting 2011*. June 3-7. Abstract No: .5585
125. Sun X, Li J, Sica G, Fan SQ, Wang Y, **Chen Z**, Muller S, Chen ZG, Shin DM, Dong JT. Mislocalization of ATBF1 is associated with progression of head and neck squamous cell carcinoma. *AACR 102nd annual meeting 2011*. April 2-6, Abstract No: 4004
126. Zhang H, Nannapaneni S, **Chen Z**, Saba N, Khuri FR, Chen ZG, Shin DM. Inhibition of head and neck squamous cell carcinoma growth by combination treatment of erlotinib and celecoxib: Potential chemopreventive agents. *AACR 102nd annual meeting 2011*. April 2-6, Abstract No: 841
127. Harris WB, Lingerfelt BM, **Chen Z**, Kucuk O, Osunkoya AO, Pattaras JG, Ogan K, Nieh PT, Petros JA, Young AN, Marshall FF, Master V. Simple perioperative algorithm for serum C-reactive protein: A potent, independent, adverse prognostic factor for renal cell carcinoma. *AACR 102nd annual meeting 2011*. April 2-6, Abstract No: 5169
128. Wang H and **Chen Z**. Cloud Computing: *Is It Ready for Clinical Information System?* *The 13th IEEE Joint International Computer Science and Information Technology Conference (JICSIT)*. 2011 August 20-22. Paper ID: 44

129. **Chen Z**, Tighiouart M, Krailo MD, Azen SP. An Extended Escalation with Overdose Control (EWOC) Treats Toxicity Response as a Quasi-Continuous Variable. The Society for Clinical Trials 31th Annual Meeting. 2010 May 16-19. Abstract No: A18.
130. Owonikoko TK, Behera M, **Chen Z**, Bhimani C, Curran WJ, Khuri FR, Ramalingam SS. Meta-Analysis of Second Line Chemotherapy Efficacy in Sensitive and Refractory Small Cell Lung Cancer (SCLC) Patients. 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. 2010 December 9-11, Abstract No: 105.
131. Yoshida E, Chen H, Torres M, Andic F, Liu H, Sun X, **Chen Z**, Liu T. Intra- and inter-observer variability in ultrasound-based diagnosis of normal-tissue toxicity in breast cancer radiotherapy. American Society for Therapeutic Radiology and Oncology (ASTRO) 2010 annual meeting. October 31 - November 4.
132. Hall WA, Z. **Chen Z**, Shu H, Curran WJ, Oyesiku N, Crocker IR. Safety and Efficacy of Fractionated Stereotactic Radiotherapy (FSR) and Stereotactic Radiosurgery (SRS) in the Treatment of Functioning and Non-Functioning Pituitary Tumors. American Society for Therapeutic Radiology and Oncology (ASTRO) 2010 annual meeting. October 31 - November 4.
133. Harri P, Ibraheem O, **Chen Z**, Small W, Mittal P, Bowen M, Kooby D, Staley C, Torres W. Twenty-three hour observation after liver RFA. Radiology Society of North America (RSNA) annual meeting 2010. November 28 - December 3. Abstract ID: 9003217.
134. Arepalli C, Srini T, **Chen Z**, Oshinski, J, Richer, EJ, Stillman AE, Raggi P, Tigges S. Effect Of Heart Rate, Coronary Artery Displacement And Vessel Trajectory On CT Coronary Calcium Score: A Dynamic Phantom Study. Radiology Society of North America (RSNA) annual meeting 2010. November 28 - December 3. Abstract ID: 9008741.
135. Moncayo V, Buss R, Pierre-Jerome C, Terk M, **Chen Z**. MRI quantitative assessment of the rotator cuff tendon in the painful shoulder: does thickness really matter? Radiology Society of North America (RSNA) annual meeting 2010. November 28 - December 3. Abstract ID: 9011297.
136. Harvey RD, Kauh JS, Ramalingam SS, Lewis CM, **Chen Z**, Lonial S., Blount IC, Shin DM, Khuri FR, Owonikoko TK. Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer. *American Society of Clinical Oncology Annual Meeting 2010*. June 4-8. Abstract No: 41873.
137. Pakkala S, **Chen Z**, Rimland D, Owonikoko TK, Gunthel C, Brandes JC, Saba NF, Curran WJ, Khuri FR, Ramalingam S. HIV-associated lung cancer in the era of highly active antiretroviral therapy (HAART): Correlation between CD4 count and outcome. *American Society of Clinical Oncology Annual Meeting 2010*. June 4-8. Abstract No: 51876.
138. Saba N, Marcus A, Beitler J, Muller S, Eggers C, Grist W, Chen A, **Chen Z**, Shin DM, Khuri FR. Acetylated Tubulin (AT) levels predict response to TPF chemotherapy in locally

advanced Head and Neck Squamous cell Carcinoma (HNSCC). *American Association of Cancer Research (AACR) 101st annual meeting 2010*. April 17-21.

139. Wang D, Su L, Wang Y, Amin R, Muller S, Huang D, Nannapaneni S, Koenig L, **Chen Z**, Pan L, Tighiouart M, Shin DM, and Chen G. Integrin β 1 contributes to Poor Prognosis of Squamous Cell Carcinoma of the Head and Neck (HNSCC) by Promoting Metastasis. *American Association of Cancer Research (AACR) 101st annual meeting 2010*. April 17-21.
140. Sencer SF, Oberbaum M, **Chen Z**, Zhou T, Jonas WB, Ives JA, Yu LC, McLean TW. The Efficacy of the Homeopathic Agent Traumeel S® in the Prevention and Treatment of Mucositis in Children Undergoing Stem Cell Transplantation. Society of Integrative Oncology Sixth International Conference New York Academy of Medicine November 12 and 13, 2009. Abstract No: H31.
141. Muringampurath-John D, Flowers CR, Jabbar A, Sinha R, Arellano M, Bernal-Mizrachi L, Kaufman JL, Jaye DL, **Chen Z**, Lechowicz MJ, Lonial S, Armitage JO and Khoury HJ. Prognostic Significance of Circulating Lymphoma Cells in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL). American Society of Hematology (ASH) 2009 Annual Meeting. Blood 2009 114:2947.
142. **Chen Z**, Krailo MD, Sun J, Azen SP. An Extended Isotonic Phase I Design Treating Toxicity Response as a Quasi-Continuous Variable. *The Society for Clinical Trials 30th Annual Meeting*. 2009 May 3-6. Abstract No: A13.
143. Sands S, Zhou T, **Chen Z**, O'Neil S, Finlay J. *Neuropsychological and quality of life outcome of survivors of pediatric malignant glioma. Thirteenth International Symposium on Pediatric Neuro-Oncology (ISPNO). Neuro-Oncology 2008 June Page 442*. Abstract No: LE 14.
144. Schultz KP, Chen L, **Chen Z**, Kawashima T, Oeffinger KC, Nicholson HS, Neglia JP. Health-related quality of life (HR-QOL) and chronic health conditions (CHC) in survivors of childhood acute myelogenous leukemia (AML). *Journal of Clinical Oncology 26: 2008 May 20 suppl*; Abstract No: 6590.
145. Hisaki Fujii, Geoff Cuvelier, Kevin She, Soudabeh Aslanian, Hiromi Shimizu, Amina Kariminia, Mark Krailo, Zhengjia Chen, Rob McMaster, Axel Bergman, Frederick Goldman, Stephen A. Grupp, Donna A. Wall, Andrew L. Gilman and Kirk R. Schultz. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. American Society of Hematology (ASH) 2008 Annual Meeting. Blood 2008 111:3276-3285.
146. Smita Bhatia, Mark D. Krailo, Zhengjia Chen, Laura Burden, Frederic B. Askin, Paul S. Dickman, Holcombe E. Grier, Michael P. Link, Paul A. Meyers, Elizabeth J. Perlman, Aaron R. Rausen, Leslie L. Robison, Teresa J. Vietti and James S. Miser. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive

neuroectodermal tumor of bone: a report from the Children's Oncology Group. American Society of Hematology (ASH) 2007 Annual Meeting. Blood 2007 109:46-51.

147. Leavey P, Mascarenhas L, Marina N, **Chen Z**, Krailo M, Miser J, Bernstein M, Granowetter L, Grier H. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence. *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: Abstract No: 10011.
148. Fujii H, She K, Aslanian S, Shimizu H, Krailo M, **Chen Z**, Goldman F, Wall DA, Gilman AL, Schultz KR. Inflammatory Markers and Autoantibodies That Correlate with Early and Late Onset of New Onset Pediatric Chronic Graft-Versus-Host Disease (GVHD). American Society of Hematology (ASH) 2006 Annual Meeting. Blood 2006 108:3232.
149. Nicholson SH, Zhou T, **Chen Z**, Moran K, Sklar C, Zeltzer L, Neglia J. Quality of Life in Survivors of Childhood and Adolescent Acute Myelogenous Leukemia (AML) Does Not Differ by Treatment (Bone Marrow Transplant (BMT) vs. Chemotherapy). A Report from the Children's Oncology Group (COG). American Society of Hematology (ASH) 2005 Annual Meeting. Blood 2005 106:701.
150. Goldsby R, Burke C, Nagarajan R, Zhou T, **Chen Z**, Inskip P, Marina N, Friedman D, Neglia J, Bhatia S. Solid organ second malignant neoplasms among children diagnosed with malignant bone tumors treated on Children Cancer Study Group/Pediatric Oncology Group protocols after 1980. *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006 Abstract No: 9007.
151. Jacobsohn DA, Schultz KR, Goldman F, Wall DA, Krailo M, **Chen Z**, Lipton JM, Sanders JE, Gilman AI. Eosinophilia, Positive ANA, and Hypergammaglobulinemia at Presentation of Extensive Chronic GVHD in Children: A Children's Oncology Group Study. American Society of Hematology (ASH) 2006 Annual Meeting. Blood 2005 106:5375.
152. Bhatia S, Krailo M, **Chen Z**, Burden L, Dickman P, Grier H, Link M, Meyers P, Perlman E, Robison LL, Miser J. Therapy-related myelodysplasia/ Leukemia (t-MDS/AML) following treatment of children with Ewing sarcoma and Primitive Neuroectodermal Tumor of Bone (PNET). *American Society of Clinical Oncology Annual Meeting 2005*, Orlando, Florida, US. Abstract No: 8514.
153. Ozkaynak F, Krailo M, **Chen N**, Feusner J. Randomized comparison of antibiotics alone and with granulocyte colony-stimulating factor (G-CSF) in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group. *Pediatric Blood & Cancer*; 42(6):1769a, 2004. Abstract No: 1769.
154. **Chen Z**, Wu A, Gauderman J, Bernstein L, Pike MC, Ma H, Ursin G. Ethnic differences in mammographic density. *35th Annual Meeting of the Society for Epidemiologic Research*, 2002. Palm Spring, California, US. Abstract No: 253.

Book Chapters

Pappo A, Krailo M, **Chen Z**, Reaman G. The Rare Tumor Initiative of the Children's Oncology Group: Lessons Learned in the First 6 Years and Their Effect on Future Plans. *ASCO Educational Book*; 2009.

L. INVITED TALKS

1. SRCOS 2019 Annual Meeting, Kentucky.
Date: 6/5/2019.
Topic "Advanced Phase I Clinical Trial Designs".
2. Department of Biostatistics. Washington University. St. Louis, Missouri.
Date: 6/2/2017.
Teach a workshop entitled "Commons and Innovative Designs for Phase I Clinical Trial".
3. Department of Biostatistics and Bioinformatics. Georgetown University. Washing DC.
Date: 2/27/2015.
Topic: Bayesian optimal designs for cancer Phase I clinical trials.
4. Department of Biostatistics. Washington University. St. Louis, Missouri.
Date: 3/16/2012.
Topic: Dose Escalation with Overdose Control using a Quasi-Continuous Toxicity Score in Cancer Phase I Clinical Trials.
5. Workshop of Department of Mathematics and Statistics. Georgia State University. Atlanta, Georgia.
Date: 5/6/2012.
Topic: Dose Escalation with Overdose Control using a Quasi-Continuous Toxicity Score in Cancer Phase I Clinical Trials.
6. Department of Mathematics and Statistics. Georgia State University. Atlanta, Georgia.
Date: 10/19/2010.
Topic: A Novel Toxicity Scoring System Treating Toxicity Response as a Quasi-Continuous Variable in Phase I Clinical Trials.
7. Winship Cancer Institute. Emory University. Atlanta, Georgia.
Date: 5/28/2010.
Topic: A Novel Toxicity Scoring System Treating Toxicity Response as a Quasi-Continuous Variable in Phase I Clinical Trials.
8. Department of Biostatistics and Bioinformatics. Emory University. Atlanta, Georgia.
Date: 6/14/2009.
Topic: An Extended Isotonic Phase I Design Treating Toxicity Response as a Quasi-Continuous Variable.
9. Department of Biostatistics. SUNY at Buffalo. Buffalo, New York.
Date: 6/1/2009.

Topic: An Extended Isotonic Phase I Design Treating Toxicity Response as a Quasi-Continuous Variable.

M. CLINICAL SOFTWARE DEVELOPED


1. ID-NETS (Isotonic Design using Normalized Equivalence Toxicity Score).

ID-NETS is a novel semi-parametric Phase I design which is developed by integration of original isotonic design and my NETS system. ID-NETS can substantially improve the accuracy of MTD determination and trial efficiency by fully utilizing all toxicities of each patient and treating toxicity response as a quasi-continuous variable instead of a binary indicator of DLT. ID-NETS is also very robust because it only assumes a monotonically increasing dose toxicity relationship instead of any parametric model. ID-NETS is particularly appropriate for clinical trials which have no reliable parametric model for dose toxicity relationship and the target toxicity level is outside the range of 18-33% of DLT. ID-NETS[®]™ is an interactive and user-friendly statistical software to implement the design ID-NETS in Phase I clinical trials.




2. EWOC-NETS (Escalation with Overdose Control using Normalized Equivalence Toxicity Score).

EWOC-NETS is a novel Bayesian adaptive design which is a combination of EWOC and my NETS system. EWOC-NETS not only retains all the advantages of EWOC, but also treats toxicity response as a quasi-continuous variable instead of a binary indicator of DLT, fully utilizes all toxicity information, and improves the accuracy of MTD estimation and the efficiency of Phase I trials. EWOC-NETS[®]™ is an interactive and user-friendly statistical software to implement the design EWOC-NETS in Phase I clinical trials.



3. Standard 3+3 Design simulator

Standard 3+3 with or without dose de-escalation designs are still most widely used in cancer Phase I clinical trials for their simplicity and robustness. In clinical practice and grant applications, it is necessary to provide the operating characteristics of Phase I clinical trials at the planning stage. Therefore I have developed an interactive and user-friendly software called Standard-3+3-design[®]™ to estimate the operating characteristics of Phase I clinical trials using Standard 3+3 designs.



4. Development of R code for application of Escalation with over dose and under dose control (EWOUC) design in cancer Phase I/II clinical trial. (R code available per request).
5. Development of R code for application of Escalation with Over Dose with Normalized Equivalent Toxicity Score (EWOC-NETS) design in cancer Phase I/II clinical trial. (R code available per request).
6. Extension of the R code to estimate personalized Maximum Tolerated Dose (MTD) in cancer Phase I/II clinical trial using the design: Escalation with Over Dose with Normalized Equivalent Toxicity Score (EWOC-NETS). (R code available per request)
7. Development of R code for calculation of the operating characteristics of Phase I clinical trials using Standard 3+3 designs. (R code available per request).
8. Development of an interactive statistical software for calculation of the operating characteristics of Phase I clinical trials using standard 3+3 design. (Using R shiny).
9. Development of an interactive statistical software for Phase I clinical trials using EWOC-NETS design. (Using R shiny).

N. COMPUTATION SKILLS

Statistical:

- Statistical Language: SAS (More than 12 years of experience), STATA (More than 4 years of experience), EPILOG More than (8 years of experience), SURVEY More than (3 years of experience), S-plus, SPSS, R language, etc.
- Databases: Access, Oracle, FoxPro, SQL, PL/SQL, MySQL.
- Application Software: Microsoft Word, Excel, Powerpoint, Sigma plot.

Computer Science:

- Programming languages: C/C++, Fortran.
- Platforms: Unix, Windows 95/98/2000/NT, MacOS, Linux, MS-DOS.